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ArticleSuper-Enhancer-Associated LncRNA UCA1
Interacts Directly with AMOT to Activate
YAP Target Genes in Epithelial Ovarian Cancer
Xianzhi Lin,1 Tassja J. Spindler,1 Marcos Abraa˜o de Souza Fonseca,2 Rosario I. Corona,1,3 Ji-Heui Seo,4
Felipe Segato Dezem,2 Lewyn Li,4 Janet M. Lee,3 Henry W. Long,4,5 Thomas A. Sellers,6 Beth Y. Karlan,1
Houtan Noushmehr,2,7 Matthew L. Freedman,4,5,8 Simon A. Gayther,3 and Kate Lawrenson1,3,9,*1Women’s Cancer Programat
the Samuel OschinSUMMARY
Long noncoding RNAs (lncRNAs) have emerged as critical regulators of tumorigenesis, and yet their
mechanistic roles remain challenging to characterize. Here, we integrate functional proteomics with
lncRNA-interactome profiling to characterize Urothelial Cancer Associated 1 (UCA1), a candidate
driver of ovarian cancer development. Reverse phase protein array (RPPA) analysis indicates that
UCA1 activates transcription coactivator YAP and its target genes. In vivo RNA antisense purification
(iRAP) ofUCA1 interacting proteins identified angiomotin (AMOT), a known YAP regulator, as a direct
binding partner. Loss-of-function experiments show that AMOTmediates YAP activation by UCA1, as
UCA1 enhances the AMOT-YAP interaction to promote YAP dephosphorylation and nuclear translo-
cation. Together, we characterize UCA1 as a lncRNA regulator of Hippo-YAP signaling and highlight
the UCA1-AMOT-YAP signaling axis in ovarian cancer development.
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Long noncoding RNAs (lncRNAs) are a class of noncoding transcripts over 200 nucleotides in length. They
are expressed in a highly tissue- and disease-specific manner and play critical roles in development and
disease (Derrien et al., 2012, 2012; Guttman et al., 2010, 2009; Kretz et al., 2012; Loewer et al., 2010). In can-
cer, dysregulated lncRNAs can function either as oncogenes (Calin et al., 2007; Gupta et al., 2010; Wang
et al., 2008) or tumor suppressors (Kotake et al., 2011; Wang et al., 2012). LncRNAs have emerged as critical
regulators of gene expression, with their activity largely governed by absolute expression levels, interact-
ing partners, and subcellular localization (Guttman and Rinn, 2012).
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy in the United States, with less
than 50% of patients surviving more than 5 years (Siegel et al., 2016). This is largely due to lack of effective
targeted therapies for treatment of EOC, which is often drug resistant when it recurs. So far, a handful of
lncRNAs have been implicated in EOC. H19 and HOTAIR are expressed in ovarian tumors (Qiu et al., 2014;
Tanos et al., 1999), and MEG3, DNM3OS, and MIAT are critical for epithelial-to-mesenchymal transition
(Mitra et al., 2017). However, the underlying functional mechanisms of lncRNAs in EOC development
remains poorly understood and their prospects as therapeutic targets for ovarian cancer unexplored.
For each tumor type there are typically thousands of dysregulated lncRNAs, but there is currently no
consensus on the most efficient approach to identifying and characterizing the most critical players in dis-
ease development. Here, we implement a strategy for prioritization and characterization of lncRNAs
implicated in cancer. The ‘‘LncRNA Interpreter’’ approach combines functional proteomics with interac-
tome profiling to characterize the functional and biological role of a candidate lncRNA. We established
and validated this strategy using lncRNA Urothelial Cancer Associated 1 (UCA1) as a proof of concept.
We found UCA1 overexpression is a driver of ovarian cancer development. The reverse phase protein array
(RPPA) profiling revealed deregulation of Hippo-YAP signaling whenUCA1 is depleted. Characterization of
UCA1 interacting proteins identified a mechanism of regulation of Hippo-YAP signaling via physical
interactions between UCA1 and angiomotin (AMOT), a non-canonical RNA-binding protein. The LncRNA
Interpreter approach can therefore efficiently provide critical mechanistic insights for characterization of
candidate lncRNAs.242 iScience 17, 242–255, July 26, 2019 ª 2019 The Authors.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
RESULTS
LncRNA Interpreter, a Strategy for Mechanistic Analysis of LncRNAs
An overview of LncRNA Interpreter strategy is shown in Figure 1. Following lncRNA identification (e.g., from
analysis of patient data or analyses of super-enhancer-associated lncRNAs), lncRNA knockout (KO) models
are generated for disease-relevant phenotypic characterization. The RPPA is utilized to evaluate differen-
tially expressed proteins and downstream pathways affected by disruption of lncRNAs. Most key cancer
pathways are surveyed on the RPPA (Paweletz et al., 2001), which enables quantification of several protein
post-translational modifications that are crucial for signaling cascades commonly deregulated in cancer
(Charboneau et al., 2002). We developed in vivo RNA antisense purification (iRAP) from previously
developed RNA-centric methods (Chu et al., 2015; McHugh et al., 2015; Minajigi et al., 2015) to catalog
the interacting proteome of candidate lncRNAs. As protein-RNA interactions are essential for lncRNA func-
tionality, intersection of proteins/pathways identified using RPPA with iRAP profiles provides an efficient
approach for dissecting the underlying mechanism of candidate lncRNAs implicated in complex diseases
such as cancer.UCA1 Is a Driver of Ovarian Cancer Development and Outcome
We evaluated data from The Cancer Genome Atlas (Cancer Genome Atlas Research Network, 2011) to
identify candidate lncRNAs that drive the development and clinical outcome (survival) in high-grade serous
EOC cases. We identified an lncRNA signature comprising 50 lncRNAs associated with patient prognosis
(Figure 2A, Table S1). Since super-enhancers mark pivotal oncogenes in many tumor types (Jiang et al.,
2018; Love´n et al., 2013; Peng et al., 2019; Xie et al., 2018), we integrated lncRNA expression data with
genome-wide profiles of enhancer marks generated using chromatin immunoprecipitation sequencing
(ChIP-seq) for H3K27ac in primary high-grade serous EOC tissues to identify super-enhancers that drive
candidate oncogenic lncRNA expression. Ninety-three super-enhancers identified in high-grade serous
EOC tissues were associated with lncRNA expression (Figure 2A, Table S2), of which three, UCA1,
SNHG9, and SNHG15, were also associated with prognosis (Figure 2A, Table S1). UCA1 is of particular in-
terest as this lncRNA has been implicated in the development of other cancers (Chen et al., 2016; Fang
et al., 2014; Han et al., 2014; Hughes et al., 2015; Li et al., 2014, 2016a, 2016b; Na et al., 2015; Nie et al.,
2016; Tian et al., 2014; Tuo et al., 2015; Wang et al., 2015; Zhang et al., 2016; Zhao et al., 2017; Zheng
et al., 2015), although its functional targets remain elusive. The UCA1 locus is marked by a super-enhancer
in all major histotypes of ovarian cancer—clear cell, endometrioid, high-grade serous, and mucinous—but
not in precursor tissues—fallopian tube secretory epithelial cells (FTSECs) or ovarian surface epithelial
cells (OSECs) (Figure 2B). UCA1 expression positively correlates with super-enhancer signal at this locus
(r = 0.51, p = 0.026, Spearman’s correlation) (Figure 2C), suggesting that this tumor-specific super-enhancer
regulates UCA1 expression. Super-enhancer-associated genes are particularly responsive to treatment of
(+)-JQ1 (Love´n et al., 2013), a potent inhibitor of BET family of bromodomain proteins including BRD4
(Filippakopoulos et al., 2010); we found that UCA1 expression was significantly downregulated in two
ovarian cancer cell lines treated with (+)-JQ1 compared with dimethyl sulfoxide (DMSO)-treated control
cells (Figure 2D). The expression of a neighboring gene OR10H1 (20 kb upstream), which has no
super-enhancer at its locus (Figure S1A) and shows some evidence of correlation with the UCA1 super-
enhancer (r = 0.47, p = 0.043, Spearman’s correlation) (Figure S1B), was not affected by (+)-JQ1 treatment
(Figure 2D). Together these analyses suggesting the super-enhancer at this locus drives the expression of
UCA1 in ovarian cancer.Deletion of UCA1 Impairs Ovarian Cancer Cell Growth
CRISPR/Cas9 genome editing was used to create stable UCA1 KO models in ovarian cancer cell lines
OVCA429 and OVISE (Figures 3A and 3B). UCA1 expression was undetectable in all UCA1 KOmodels (Fig-
ure 3C). The effects of UCA1 KO on in vivo tumor cell growth were established after intra-peritoneal
injection of 10 million wild-type (WT) UCA1 or UCA1 KO cells in nude mice. The mass of resulting tumors
was significantly smaller in UCA1 KO models compared with those in mice injected with WT cells
(OVCA429 p = 0.002; OVISE p = 0.002) (Figures 3D and 3E), indicating that UCA1 acts as a potent promoter
of tumor seeding and/or growth in vivo.UCA1 Regulates Hippo-YAP Signaling in Ovarian Cancer
We used RPPAs to profile changes in protein abundance and phosphorylation following UCA1 KO. The
most differentially expressed proteins between WT and UCA1 KO cells included phosphorylated YAP atiScience 17, 242–255, July 26, 2019 243
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Figure 1. LncRNA Interpreter, a Strategy for Mechanistic Analysis of lncRNAs
The LncRNA Interpreter strategy consists of five major components. (A) Discovery of candidate lncRNAs is performed using patient specimens. (B)
Phenotypic characterization of the candidate lncRNA is performed in vitro and in vivo using KO cancer cell models generated using CRISPR/Cas9 genome
editing technique. (C) Proteins affected by candidate lncRNA are identified by functional proteomics using RPPA. (D) LncRNA interacting proteins are
identified using iRAP. (E) RPPA and iRAP data are integrated to identify common protein targets. ChIP-seq, chromatin immunoprecipitation sequencing;
RNA-Seq, RNA sequencing; RPPA, reverse phase protein array; iRAP, in vivo RNA antisense purification; WT, wild-type; KO, knockout; RBP, RNA-binding
protein; RIP, RNA immunoprecipitation; MS, mass spectrometry; WB, western blotting; RT-qPCR, reverse transcription quantitative polymerase chain
reaction.Ser127 (YAPpS127, fold change [FC] = 1.3, p = 0.038), AXL (FC = 0.75, p = 0.031), and PUMA (FC = 1.18,
p = 0.042), all of which belong to the Hippo-YAP signaling pathway (Figure 4A, Table S3). YAPpS127 is
retained in the cytoplasm via binding to 14-3-3 protein, which leads to inhibition of downstream YAP
signaling (Zhao et al., 2010). We observed an increased expression of YAPpS127 and pro-apoptotic YAP
target gene PUMA (Matallanas et al., 2007) and decreased expression of the pro-proliferative YAP target
gene AXL (Xu et al., 2011) in UCA1 KO compared with WT cells (Figure 4A), indicating that UCA1 activates
Hippo-YAP signaling for cell survival and proliferation. Consistent with this, YAPpS127 protein expression is
significantly lower in primary tumors with UCA1 overexpression or amplification (n = 105, average
abundance 0.25) compared with tumors with no UCA1 overexpression (n = 477, average abundance
0.07, p = 2.83104,Q = 0.019) (Figure S2A). There was no significant difference in total YAP protein expres-
sion between the two groups (Figure S2B), suggesting that UCA1 also activates YAP signaling in vivo.
Since the presence of a non-unique intronic sequence mandated the introduction of a >5 kb deletion to KO
UCA1, it is plausible that noncoding elements within the UCA1 locus activate YAP target genes in cis or in
trans. To test this possibility, loss-of-function experiments using small interfering RNAs (siRNAs) specific to
UCA1 were conducted to validate the role of UCA1 in regulation of Hippo-YAP signaling. After UCA1
knockdown (KD) in high-grade serous ovarian cancer cell lines (Figure 4B), total YAP expression was
unaltered, whereas YAPpS127 was elevated at least 50% in all three ovarian cancer cell lines (by ImageJ)
(Figure 4C), consistent with RPPA results in UCA1 KO cells and primary tissues. YAP regulates the expres-
sion of AXL and CYR61 at both RNA (Figure 4D) and protein levels (Figure 4E), indicating that AXL and
CYR61 are indeed YAP targets in ovarian cancer. The effect of UCA1 KD on the abundance of AXL and
CYR61 largely phenocopied YAP KD (Figures 4C and 4E). Moreover, gain-of-function experiments per-
formed by overexpressing UCA1 in TERT-immortalized, MYC-expressing normal ovarian epithelial cells
(OSEC4C2) (Figure 4F) demonstrated that overexpression of UCA1 increased the expression of YAP target
genes AXL, CYR61, as well as CTGF (Figure 4G). Consistent with the loss-of-function experiments, overex-
pression of UCA1 inhibits YAP phosphorylation but does not affect total YAP expression (Figure 4G). Taken
together, these data indicate that UCA1 activates Hippo-YAP signaling in ovarian cancer.iRAP Catalogs the UCA1 Interacting Proteome
Proteins purified from two independentUCA1-iRAP experiments were profiled bymass spectrometry. Each
iRAP experiment included two non-overlapping UCA1 probe sets (UCA1-odd, UCA1-even) for cross-
validation and a U1 probe as positive control (Figure S3A, Table S4). The iRAP assay was highly specific:
both UCA1 probe sets significantly enriched UCA1 but not U1 snRNA; conversely, the U1 probe enriched
U1 snRNA but not UCA1. As expected, U6 snRNA was not enriched by any of the probes (Figure S3B).
iRAP-MS recovered 86 U1-associated proteins (Figure 5A), including six known U1 direct binding proteins
and another 35 U1-associated proteins (Figure S3C, Table S5) (Chu et al., 2015). These data indicate that
iRAP efficiently identifies bona fide RNA-binding proteins associated with a specific target transcript.
We isolated 47 and 42 proteins, respectively, using UCA1-odd and UCA1-even probe sets (Figure 5A).
Thirty-eight proteins were only associated with UCA1, 19 of which were identified by both sets of probes
(Figure 5A). In most instances the same peptide was retrieved by both UCA1 probe sets across the two
experiments (Figures 5B and S3D, Table S5), suggesting that these 19 proteins are true UCA1-binding
proteins.UCA1 Interacts Directly with Hippo-YAP Signaling Regulator AMOTp130
We intersected the UCA1 interacting proteome with the pathways identified in the RPPA profiling
described earlier. This highlighted AMOT, a known regulator of Hippo-YAP signaling (Moleirinho et al.,
2017; Zhao et al., 2011). A peptide mapping to amino acids 727–740 of AMOT was identified by both
UCA1 probe sets in two independent experiments (Figure 5B), suggesting this predicted coiled-coiliScience 17, 242–255, July 26, 2019 245
Figure 2. UCA1 in Ovarian Cancer Development and Outcome
(A) In high-grade serous EOCs a signature of 50 lncRNAs was prognostic. Using tumor tissue H3K27ac data, 93
high-grade serous EOC super-enhancer-associated lncRNAs were identified. 3 lncRNAs were shared between the
two analyses.
(B) UCA1-associated super-enhancer is present across the four major histological subtypes of EOC, but not normal
precursor cells. H3K27ac ChIP-seq signal is shown in log scale. CCOC, clear cell ovarian cancer; EnOC, endometrioid
ovarian cancer; HGSOC, high-grade serous ovarian cancer; MOC, mucinous ovarian cancer.
(C) Super-enhancer signal positively correlates withUCA1 expression (Spearman’s correlation, r = 0.51, p = 0.026). Counts
per million (CPM) of UCA1 from RNA-seq is shown. Super-enhancer signals were normalized using TMM (Robinson and
Oshlack, 2010). We did not have sufficient tissue to do RNA-seq for one EnOC tumor (#3), and one HGSOC tumor (#4)
does not express UCA1.
(D) UCA1 expression is sensitive to JQ1 treatment in HGSOC models. Two HGSOC cell lines (CaOV3, UWB1.289) were
treated with (+)-JQ1 or DMSO. The expression of UCA1 and OR10H1 was measured by RT-qPCR.
Data shown here are mean G SD from three independent experiments. ***p = 13107 (CaOV3), ***p = 23108
(UWB1.289), ns, not significant, Student’s t test. See also Figure S1, Tables S1 and S2.domain of AMOT is responsible for the interaction with UCA1. AMOT exists as two isoforms,
AMOTp130 and AMOTp80, a shorter isoform that lacks 409 amino acids at the N terminus due to alternative
splicing of the AMOT gene between exon 2 and 3 (Ernkvist et al., 2006). Western blotting of iRAP lysates
validated the AMOT-UCA1 interaction. We observed shifted AMOTp130 (to around 160 kDa) but not
AMOTp80, suggesting that UCA1 associates specifically with AMOTp130 (Figure 5C). To further verify
the AMOT-UCA1 interaction, we performed RNA immunoprecipitation (RIP) using an anti-AMOT antibody
(Table S6). Western blotting for AMOT confirmed successful pull-down of both AMOTp80 and AMOTp130
isoforms (Figure 5D), and an 2- to 5-fold enrichment of UCA1 was detected in AMOT-RIP samples
compared with corresponding control isotype IgG pulldowns (CaOV3, p = 7.43106; OVCA429, p =
0.011; UWB1.289, p = 7.23107) (Figure 5E). We noted that a higher ratio of AMOTp130/p80 correlates
with a higher fold enrichment of UCA1 (Figures 5D and 5E), further suggesting that UCA1 preferentially
associates with AMOTp130. To validate this, we overexpressed GFP-AMOTp130 or GFP-AMOTp80 in246 iScience 17, 242–255, July 26, 2019
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Figure 3. Inactivation of UCA1 Impairs Ovarian Cancer Cell Growth
(A) Schematic of CRISPR/Cas9 genome editing strategy for UCA1 knockout.
(B) Long-range PCR of parental (OVCA429 and OVISE) cells, control cells expressing the gRNA vector backbone, and two
stable UCA1 knockout clones from each cell line (UCA1 KO-1, UCA1 KO-2).
(C) The expression of UCA1,measured by RT-qPCR, was normalized to the expression of GAPDH and b-actin in the UCA1
KO models, parental cells, and control cells. Data shown are mean G SD from three independent experiments.
(D) Images of excised tumors from mouse xenograft model. Scale bar represents 1 cm.
(E) Tumor weight of xenografted UCA1 KO ovarian cancer cells and parental controls. **p < 0.01, Student’s t test.EOCcells andperformedGFP-RIP.Western blotting validated successful pull-downof bothGFP-AMOTp80
andGFP-AMOTp130 (Figure 5F) with significant enrichment ofUCA1 observed for GFP-AMOTp130 but not
GFP-AMOTp80 (Figure 5G), despite the markedly more efficient pull-down of AMOTp80 (Figure 5F). These
data together indicate that UCA1 interacts directly with AMOTp130 but not AMOTp80.
AMOTp130 but not AMOTp80 was previously reported to interact with YAP and regulate its activity (Sowa
et al., 2009; Zhao et al., 2011). We tested whether this interaction is intact in EOC. In YAP-RIP experiments,
AMOTp130 was detected in YAP pull-downs (Figure 5H), confirming that YAP interacts with AMOTp130.
AMOTp80 was also detected in YAP pull-downs for two of the three cell lines, which may be due
to hetero-oligomerization (Ernkvist et al., 2008; Patrie, 2005; Zheng et al., 2009). Interestingly, a 4- to
29-fold enrichment of UCA1 was detected in YAP pulldowns compared with IgG isotype controls (Fig-
ure 5I). Since we did not identify YAP using iRAP (which preferentially detects direct binding proteins),
these data suggest that YAP, AMOTp130, and UCA1 form a trimer complex with AMOTp130 bridging
the interaction between YAP and UCA1. Once formed, the AMOTp130-YAP interaction is independent
of UCA1 since the association still exists following RNase A treatment (Figures 5J and 5K).iScience 17, 242–255, July 26, 2019 247
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Figure 4. UCA1 Activates Hippo-YAP Signaling in Ovarian Cancer
(A) RPPA analyses of OVCA429 UCA1 KO cells and controls. All proteins with significant changes (FC > 1.2 or <0.9 and p% 0.05) in abundance are shown.
Proteins highlighted in blue are involved in Hippo-YAP signaling.
(B) The expression of UCA1 was measured by RT-qPCR and normalized to b-actin in both scramble control siRNA (siCtrl) and UCA1-specific siRNA (siUCA1)-
transfected CaOV3, OVCA429, and UBW1.289 cells. Data shown are mean G SD from three independent experiments.
(C) The expression of YAP, YAPpSer127, and YAP targets by western blotting in both siCtrl and siUCA1-transfected cells. Representative results from
three independent experiments are shown. When UCA1 was knocked down, YAPpSer127 expression was elevated 90% (p < 0.01), 150% (p < 0.001), and 50%
(p < 0.05) in CaOV3, OVCA429, and UWB1.289 cells, respectively. Student’s t test.
(D) The expression of YAP targets AXL and CYR61 was measured by RT-qPCR in siCtrl and siYAP-transfected cells and normalized to b-actin. Data shown are
mean G SD from three independent experiments. **p < 0.01, ***p < 0.001, Student’s t test.
(E) The expression of YAP and YAP targets by western blotting in CaOV3, OVCA429, and UBW1.289 cells transfected with siCtrl or siYAP.
(F) The Ct values of UCA1 lncRNA in both OSEC4C2 control cells and OSEC4C2 cells with UCA1 overexpression. ND, not detected. Data shown are
mean G SD from three independent experiments and normalized to 18S rRNA.
(G) The expression of YAP, YAPpSer127, and YAP targets by western blotting in both OSEC4C2 control cells and OSEC4C2 cells with UCA1 overexpression.
b-Actin was used as loading control for western blotting.
See also Figure S2 and Table S3.UCA1 Activates YAP and Target Genes by Enhancing the AMOTp130-YAP Interaction to
Promote YAP Dephosphorylation and Nuclear Translocation
We next tested whether AMOT is required for activation of YAP target genes by UCA1. Western blotting
and RT-qPCR validated the successful depletion of AMOT (Figure 6A) and UCA1 (Figure 6B), respectively.
Both UCA1 and AMOT KD resulted in reduced expression of AXL and CYR61 and elevated the expression
of YAPpS127 40%–100% but had no effect on total expression levels of YAP, YAP kinase LATS1, or active
pLATS1 (Figure 6A). Although the expression of UCA1 was not affected by AMOT KD (Figure 6B), the248 iScience 17, 242–255, July 26, 2019
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Figure 5. UCA1 Interacts Directly with Hippo-YAP Signaling Regulator AMOTp130
(A) iRAP followed by mass spectrometry to catalog the UCA1 interactome.
(B) The same AMOT peptides were reproducibly retrieved from UCA1 iRAP. Numbers indicate the amino acid position; protein not drawn to scale. Data
shown are from two independent experiments.
(C) Western blotting validation of AMOT as a direct binding protein for UCA1 using iRAP samples. U1-70k, a known direct binding protein for U1 snRNA, is
used as positive control for U1. As expected, GAPDH binds neither U1 nor UCA1.
(D and E) RIP validation of the AMOT-lncRNA UCA1 interaction. (D) Western blotting validation of AMOT pull-down, using an AMOT specific antibody, in
three high-grade serous EOC cell lines. Isotype IgG was included as negative control. Numbers beneath the blots are the relative ratios for
AMOTp130:AMOTp80. (E) Relative expression of UCA1 in AMOT immunoprecipitated RNA samples by RT-qPCR.
(F and G) RIP validation of AMOTp130-UCA1 interaction. (F) Western blotting validation of GFP-tagged AMOT pull-down with an anti-GFP antibody.
Representative images from three independent experiments are shown. Control cells were transduced with a GFP expressing vector only. (G) Relative
expression of UCA1 for GFP-RIP samples by RT-qPCR. # denotes a non-specific band observed with this GFP antibody. (H-I) RIP validation of
YAP-AMOTp130-UCA1 complex.
(H) Western blotting validation of YAP pull-down and AMOT co-immunoprecipitated using a YAP specific antibody. Isotype IgG was included as
negative control.
(I) RT-qPCR measurement of relative expression of UCA1 in YAP-RIP samples.
(J) RIP following RNase A treatment, UCA1 is not required for the YAP-AMOTp130 interaction. Western blotting validation of YAP pull-down and AMOT
co-immunoprecipitated by YAP specific antibody, with or without RNase A treatment. Isotype IgG was included as negative control.
(K) Relative expression of UCA1 by RT-qPCR in YAP RIP samples, incubated with or without RNase A.
Data shown are meanG SD from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, Student’s t test. See also Figure S3, Tables S4 and S5.
iScience 17, 242–255, July 26, 2019 249
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Figure 6. UCA1 Activates YAP and Its Target Genes by Facilitating AMOTp130-YAP Interaction to Promote YAP Dephosphorylation and Nuclear
Translocation
(A) AMOTmediates the activation of YAP and its target genes by UCA1. OC cells were transfected with siCtrl, siAMOT, or siUCA1 for 72 h. Whole-cell lysates
were prepared and blotted with antibodies indicated. When UCA1 or AMOT is knocked down, YAPpSer127 expression is elevated 80% (p < 0.01), 100%
(p < 0.01), and 40% (p < 0.01) in CaOV3, OVCA429, and UWB1.289 cells, respectively.
(B) Validation of siRNA knockdown efficiency for UCA1. Relative expression of UCA1 by RT-qPCR for samples is shown in (A).
(C) UCA1 KO in OVCA429 cells decreases nuclear YAP. UCA1 wild-type (Ctrl1, Ctrl2) or knockout (KO-1, KO-2) OVCA429 cells were fractionated into
cytoplasmic (Cy) and nuclear (Nu) fractions and blotted for b-tubulin (a cytoplasmic marker), U1-70k (a nuclear marker), and YAP.
(D) Quantification of nuclear YAP using ImageJ.
(E) UCA1 KD decreases nuclear YAP. CaOV3, OVCA429, and UWB1.289 cells transfected with control siRNAs or siUCA1 were fractionated into cytoplasmic
and nuclear fractions and blotted for b-tubulin, U1-70k, AMOT, and YAP. Nuclear YAP is reduced 50% (CaOV3, p < 0.05) and 70% (UWB1.289, p < 0.05) in cells
transfected with siUCA1.
(F) UCA1 overexpression in OSEC4C2 cells increases nuclear YAP. OSEC4C2 control cells and OSEC4C2 cells with UCA1 overexpression were fractionated
into Cy and Nu fractions and blotted for b-tubulin, U1-70k, and YAP. Nuclear YAP is elevated 30% (p < 0.05).
(G) UCA1 facilitates AMOTp130 binding to YAP. High-grade serous EOC cell lines were transfected with siCtrl or siUCA1 for 72 h. Co-immunoprecipitation
experiments were performed using an anti-YAP antibody. Retrieval of AMOT is reduced 70% (CaOV3, p < 0.05) and 50% (UWB1.289, p < 0.05) in cells
transfected with siUCA1.
(H) Working model for AMOT-mediated activation of YAP and target genes by UCA1.
SE, super-enhancer. ImageJ was used for quantification of proteins in (A, C, E, F, and G) from three independent replicates. Data shown in (B and D) are
mean G SD from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ns, not significant, Student’s t test. See also Figure S4.activation of YAP target genes was dampened (Figure 6A), indicating that AMOTmediates the activation of
YAP target genes by UCA1.
When phosphorylated at Ser127, YAP protein is retained in the cytoplasm and downstream signaling is
repressed (Zhao et al., 2010). When total YAP protein levels are constant, increased YAPpS127 should result
in reduced nuclear YAP. We therefore compared nuclear YAP expression between control and UCA1 KO
cells using cellular fractionation. Successful fractionation of the OVCA429 KO model was verified using
cytoplasmic protein marker b-tubulin and nuclear protein marker U1-70k (Figure 6C) as well as cytoplasmic
RNA marker 18S rRNA and nuclear RNA marker U6 snRNA (Figure S4A). These data show that UCA1
predominantly localizes to the cytoplasm (94% on average, Figure S4A). Nuclear YAP expression
decreased 2-fold in UCA1 KO cells (KO-1 and KO-2) compared with WT cells (Ctrl 1 and Ctrl 2) (p =
33104) (Figures 6C and 6D). In addition, fractionation experiments were performed in three ovarian can-
cer cell lines followingUCA1 KD. Similarly, nuclear YAP was reduced 2-fold inUCA1 KDCaOV3 and 3-fold in
UCA1 KD UWB1.289 cells compared with control siCtrl-treated cells (p = 0.014 and p = 0.006, respectively)
(Figure 6E). Fractionation experiments were also conducted in OSEC4C2 cells overexpressing with control
vector or UCA1 (Figures 6F and S4B). Predominant cytoplasmic expression UCA1 was confirmed in
OSEC4C2 cells overexpressing UCA1 (Figure S4B) and nuclear YAP was increased (Figure 6F). These
data indicate that cytoplasmic UCA1 activates YAP target genes via dephosphorylation and nuclear trans-
location of YAP.
Since UCA1 KD affects neither AMOT protein expression (Figure 6A) nor localization (Figure 6E), we tested
whether UCA1 affects the AMOT-YAP interaction. Two-fold less AMOTp130 coimmunoprecipitated with
YAP when UCA1 was depleted (Figure 6G), evidence that UCA1 promotes AMOTp130-YAP interaction.
In summary, we propose a model in which cytoplasmic UCA1 binds to AMOT to facilitate an interaction be-
tween AMOT and YAP, which prevents the pLATS1/2-YAP interaction and YAP phosphorylation. The net
result is a larger pool of active YAP, which relocates to the activate YAP target genes (Figure 6H).
DISCUSSION
UCA1 is conserved in primates and expressed highly in the early embryo but not in most adult tissues
(Wang et al., 2008). Originally UCA1 was found to be overexpressed in bladder carcinoma (Wang et al.,
2006) and was later shown to be upregulated in many other malignancies (Chen et al., 2016; Fang et al.,
2014; Han et al., 2014; Hughes et al., 2015; Li et al., 2014, 2016a, 2016b; Na et al., 2015; Nie et al., 2016;
Tian et al., 2014; Tuo et al., 2015; Wang et al., 2015; Zhang et al., 2016; Zhao et al., 2017; Zheng et al.,
2015). Multiple underlying mechanisms have been proposed to explain the pro-oncogenic effects of
UCA1, including inhibition of p27 (Han et al., 2014), activation of Wnt/b-Catenin signaling (Yang et al.,
2016), promotion of KLF4-KRT6/13 signaling (Na et al., 2015), or function as miRNA sponge (Bian et al.,
2016; Fang et al., 2017; He et al., 2017; Li et al., 2015, 2017, 2018; Lu et al., 2017; Nie et al., 2016; Sun
et al., 2018; Tian et al., 2018; Tuo et al., 2015; Wang et al., 2015; Wu and Zhou, 2018; Xiao et al., 2017;iScience 17, 242–255, July 26, 2019 251
Xue et al., 2016; Zhang et al., 2017; Zhou et al., 2018, 2017; Zhu et al., 2018). However, the mechanistic
pathways directly regulated by UCA1 are unclear.
In our study, we found that UCA1 overexpression drives ovarian cancer development. Our functional
proteomic analyses of UCA1 KO models revealed that UCA1 activates YAP and its target genes, which
may account for UCA1’s tumor growth promotion phenotype. To dissect the underlying mechanism of
how UCA1 activates YAP and its target gens, iRAP was performed and revealed thatUCA1 directly interacts
with AMOTp130. AMOT was initially reported as a negative regulator of YAP via cytoplasmic retention of
YAP protein (Zhao et al., 2011). However, more recent evidence suggests that AMOT can both negatively
(Chan et al., 2011; Dai et al., 2013; Paramasivam et al., 2011; Wang et al., 2011) and positively regulate
(Lv et al., 2016; Yi et al., 2013) YAP. In the present study, we demonstrated that AMOT is a positive regulator
of YAP and its targets genes in ovarian cancer. In the cytoplasm of EOC cells, overexpressed UCA1 en-
hances the interaction between AMOTp130 and YAP. This may be due to a conformational change of
AMOTp130 induced by UCA1 binding; alternatively, UCA1may affect the phosphorylation of AMOTp130,
which in turn regulates AMOTp130-YAP interaction and subcellular localization of the complex (Dai et al.,
2013; Moleirinho et al., 2017). However, the latter situation is unlikely as UCA1 does not affect AMOT local-
ization in EOC (Figure 6E). The enhanced AMOTp130-YAP interaction is thereforemore likely to antagonize
the pLATS1/2-YAP interaction that leads to phosphorylation of YAP (Yi et al., 2013) since overlapping
regions of YAP bind to AMOT or LATS1/2 (Hao et al., 2008; Zhao et al., 2011). The indirect impact of
UCA1 is therefore dephosphorylation of YAP, which in turn promotes nuclear translocation of YAP and
facilitates its binding to TEAD to activate expression of a pro-oncogenic gene signature.
In the current study, we develop a strategy LncRNA Interpreter to prioritize and then functionally dissect
candidate lncRNAs in cancer. Using this approach, we reveal UCA1 as a super-enhancer-regulated lncRNA
in EOC and an unconventional lncRNA regulator of Hippo-YAP signaling and characterize a critical function
for UCA1 in the activation of YAP and its target genes in EOC. Our data implicate the UCA1-AMOTp130-
YAP signaling axis in the development of EOC that may represent a potential target for therapeutic
intervention. More broadly, this proof-of-concept study demonstrates that the protein-centric LncRNA
Interpreter strategy can be readily applied to efficiently elucidate the functional role of other lncRNAs
implicated in complex diseases.Limitations of the Study
In this study, we demonstrated thatUCA1 activates the transcription coactivator YAP and its target genes in
both gain-of-function and loss-of-function experiments. It is plausible that UCA1 prevents YAP phosphor-
ylation by pLATS1/2, but direct evidence for this is missing owing to the low expression of LATS1/2 in our
models. Future studies evaluating YAP and AMOTp130 post-transcriptional modifications would likely
yield a deeper mechanistic insight into the regulation of Hippo-YAP signaling pathway by UCA1.METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.SUPPLEMENTAL INFORMATION
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Figure S1. No evidence of super-enhancer activity at the OR10H1 gene locus, Related to Figure 2 
(A) H3K27ac signal at the OR10H1 gene locus is shown at log scale. (B) Super-enhancer signals positively 
correlate with OR10H1 expressions (Spearman’s correlation, r=0.47, P=0.043). Counts per million (CPM) of 
UCA1 from RNA-Seq is shown. 
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Figure S2. Overexpressed UCA1 correlates with lower YAP phosphorylation in primary high-grade 
serous EOCs, Related to Figure 4A 
(A) Comparison of RPPA data for YAPpS127 between ovarian cancers with (Altered) or without (Unaltered) 
UCA1 amplification. (B) Total YAP is not significantly different between the two groups. Z-score threshold 
was set at 2. Data are from TCGA (http://www.cbioportal.org). P-value was determined using Student’s t-test, 
while the Q-value was derived from Benjamini-Hochberg procedure. 
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Figure S3. iRAP identifies the direct interacting proteome of UCA1, Related to Figure 5A 
 
(A) Probe designing for UCA1-iRAP. Two sets of non-overlapping antisense DNA probes for UCA1 were 
designed and labeled with biotin at their 3’ end. An antisense DNA probe complementary to 1-20 nt of U1 
snRNA was included as a positive control.  (B) RT-qPCR analysis of RNA retrieved from iRAP experiments. 
Data shown are mean ± SD from 4 independent experiments. (C) Peptides were retrieved from U1 iRAP-MS for 
direct binding proteins of U1 snRNA. Numbers indicate the starting amino acid position and the ending amino 
acid position of the peptide retrieved or the full length of target protein. Protein length is not drawn in scale. (D) 
The same peptides were reproducibly retrieved from UCA1 iRAP-MS experiments. A selection of 
representative proteins is shown. Numbers indicate the starting amino acid position and the ending amino acid 
position of the peptide retrieved or the full length of target protein. Protein length is not drawn in scale. Data 
shown are from 2 independent experiments.  
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Figure S4. LncRNA UCA1 predominantly localizes in cytoplasm, Related to Figure 6 
(A) RT-qPCR measurement of cytoplasmic 18S rRNA, nuclear U6 snRNA and UCA1 in OVCA429 
fractionated samples. (B) RT-qPCR measurement of cytoplasmic 18S rRNA, nuclear U6 snRNA and UCA1 in 
OSEC4C2 fractionated samples. Data shown are mean ± SD from 3 independent experiments. 
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Table S1. Prognostic lncRNAs in high-grade serous EOC, Related to Figure 2A 
LncRNA Name Importance-score Raw-score Chr Start End Width Strand Gene Type 
TTTY14 1.06572E+13 1.723 chrY 18872501 19077416 204916 - lincRNA 
PSMB1 99159107045 2.907 chr6 170535117 170553341 18225 - protein_coding 
ZFAS1 48072327683 2.585 chr20 49278178 49295738 17561 + antisense 
TUG1 40492304785 1.923 chr22 30970677 30979395 8719 + antisense 
FGD5-AS1 35063860805 2.147 chr3 14920347 14948424 28078 - antisense 
RP11-554D15.1 29197615843 -1.956 chr6 74069451 74690727 621277 + lincRNA 
CTB-55O6.12 23922544460 1.501 chr19 14137179 14171267 34089 + antisense 
GAS5 22959917722 3.715 chr1 173863900 173868882 4983 - processed_transcript 
RP5-1061H20.4 22563332287 2.269 chr1 229258281 229271028 12748 - lincRNA 
RP11-64D24.2 18447025405 2.552 chr11 114210616 114356571 145956 - antisense 
RP11-6N17.9 17963712426 1.799 chr17 47945424 47974438 29015 + processed_transcript 
OIP5-AS1 16976708028 2.315 chr15 41283990 41309737 25748 + processed_transcript 
SNHG15 16315350372 2.006 chr7 44983023 44986961 3939 - lincRNA 
RP11-865I6.2 15818503929 1.567 chr8 68848742 68852763 4022 - lincRNA 
ILF3-AS1 15338973685 1.479 chr19 10651862 10653844 1983 - lincRNA 
SNHG8 11732839093 2.472 chr4 118278709 118279823 1115 + lincRNA 
NOP14-AS1 11574773571 1.796 chr4 2934899 2961738 26840 + antisense 
LINC00662 11461006830 1.478 chr19 27684580 27793940 109361 - lincRNA 
AC005083.1 10597230777 2.135 chr7 20217577 20221700 4124 + processed_transcript 
LINC00648 10263227364 2.269 chr14 47764954 47795092 30139 - lincRNA 
AC004112.4 10158300092 2.129 chr7 112328189 112409623 81435 - antisense 
RP4-758J18.2 9884322048 1.601 chr1 1399522 1402046 2525 + processed_transcript 
RP11-38J22.3 9686546170 3.22 chr1 206117783 206126805 9023 + antisense 
RP11-458F8.4 7896100113 1.608 chr7 66902857 66906297 3441 + lincRNA 
SNHG9 7431812371 1.628 chr16 1964959 1965509 551 + lincRNA 
AJ006995.3 7240196117 -1.844 chr21 27954922 27985295 30374 + lincRNA 
LINC00339 6936706793 2.163 chr1 22024531 22031225 6695 + lincRNA 
LINC00578 6647351610 2.907 chr3 177441921 177752305 310385 + lincRNA 
RP11-47A8.5 6296575822 2.823 chr10 102642792 102644140 1349 - lincRNA 
SNHG17 6267686164 3.08 chr20 38420588 38435353 14766 - processed_transcript 
LINC00910 6258879085 2.145 chr17 43369845 43389199 19355 - lincRNA 
OSER1-AS1 6149104986 2.444 chr20 44210960 44226027 15068 + lincRNA 
C8orf31 6007255795 1.443 chr8 143039209 143059942 20734 + processed_transcript 
RP5-1132H15.1 5980054129 1.991 chr7 66119603 66165011 45409 - antisense 
 6 
RP11-430C7.4 5776440431 2.282 chr1 204603035 204616565 13531 + antisense 
RP11-191L9.4 5456541984 1.633 chr22 47631674 47855600 223927 + lincRNA 
RP11-115C21.2 5322360392 2.492 chr8 6403551 6407142 3592 - antisense 
RP11-296I10.3 5160521700 2.558 chr16 70156340 70173448 17109 - antisense 
UCA1 5062358192 1.923 chr19 15828961 15836320 7360 + processed_transcript 
RP11-799D4.4 5028502297 1.529 chr17 35231450 35242963 11514 - antisense 
RP11-526P5.2 4914956869 4.806 chr10 2501783 2567239 65457 + lincRNA 
LINC00284 4896454541 2.783 chr13 43908669 44030461 121793 + lincRNA 
FAM157C -4806404688 2.891 chr16 90102271 90186204 83934 + lincRNA 
CTC-444N24.11 -5585259828 1.666 chr19 57304305 57308562 4258 + lincRNA 
C1orf132 -5802882217 1.689 chr1 207801518 207879096 77579 - lincRNA 
RMRP -6118555929 1.777 chr9 35657751 35658018 268 - lincRNA 
RAD51-AS1 -7420839971 1.729 chr15 40686724 40695107 8384 - processed_transcript 
MIR205HG -17249780561 1.462 chr1 209428820 209432838 4019 + processed_transcript 
RASSF8-AS1 -23114357641 2.725 chr12 25939329 25959765 20437 - antisense 
NEAT1 -29777169121 1.896 chr11 65422774 65445540 22767 + lincRNA 
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Table S2. Super-enhancer-associated lncRNAs in high-grade serous EOCs, Related to Figure 2A 
LncRNA Name Chr Start End Width Strand Gene Type 
ZNF503-AS2 chr10 77160759 77168738 7980 + processed_transcript 
ZEB2-AS1 chr2 145275664 145279058 3395 + antisense 
ZBTB11-AS1 chr3 101395274 101398061 2788 + antisense 
WT1-AS chr11 32457064 32480315 23252 + antisense 
UNC5B-AS1 chr10 72976981 72977985 1005 - antisense 
UCA1 chr19 15939771 15947130 7360 + processed_transcript 
UBXN8 chr8 30589764 30624522 34759 + processed_transcript 
TMPRSS4-AS1 chr11 117886487 117957508 71022 - antisense 
TMEM72-AS1 chr10 45306472 45455137 1E+05 - antisense 
THAP9-AS1 chr4 83814162 83822113 7952 - antisense 
TFAP2A-AS1 chr6 10409573 10416679 7107 + antisense 
STK4-AS1 chr20 43592435 43595043 2609 - lincRNA 
SSSCA1-AS1 chr11 65337131 65337744 614 - antisense 
SRP14-AS1 chr15 40331512 40359491 27980 + lincRNA 
SPPL2B chr19 2328614 2355099 26486 + processed_transcript 
SNORA67 chr17 7476144 7485342 9199 + processed_transcript 
SNORA59B chr17 19460524 19461224 701 + sense_intronic 
SNHG9 chr16 2014960 2015510 551 + lincRNA 
SNHG16 chr17 74553848 74561430 7583 + processed_transcript 
SNHG15 chr7 45022622 45026560 3939 - lincRNA 
SNHG10 chr14 95998634 96001209 2576 - antisense 
SNHG1 chr11 62619460 62623386 3927 - processed_transcript 
SNAI3-AS1 chr16 88729706 88753594 23889 + antisense 
SLC2A1-AS1 chr1 43424720 43449029 24310 + lincRNA 
SENP3-EIF4A1 chr17 7466604 7482033 15430 + processed_transcript 
SEMA3B chr3 50304990 50314977 9988 + processed_transcript 
RPS10P7 chr1 201487831 201499602 11772 + lincRNA 
RNF157-AS1 chr17 74136637 74150731 14095 + antisense 
PTOV1-AS1 chr19 50341896 50354933 13038 - antisense 
PSMG3-AS1 chr7 1609709 1629262 19554 + lincRNA 
PROSER2-AS1 chr10 11891612 11936699 45088 - antisense 
PLAC4 chr21 42548249 42558715 10467 - antisense 
PDCD4-AS1 chr10 112629626 112631991 2366 - antisense 
PCOLCE-AS1 chr7 100187025 100201829 14805 - antisense 
PCED1B-AS1 chr12 47599681 47610239 10559 - processed_transcript 
PCBP1-AS1 chr2 70189395 70315978 1E+05 - antisense 
NEAT1 chr11 65190245 65213011 22767 + lincRNA 
MYLK-AS1 chr3 123304389 123363415 59027 + antisense 
MRPL23-AS1 chr11 2004467 2011150 6684 - antisense 
MIR29B1 chr7 130561495 130598069 36575 - lincRNA 
MIR22HG chr17 1614805 1620468 5664 - lincRNA 
MIR210HG chr11 565660 568457 2798 - lincRNA 
MIR194-2 chr11 64658827 64660921 2095 - lincRNA 
MIR142 chr17 56408245 56409869 1625 - antisense 
MIR10A chr17 46656992 46659621 2630 - sense_intronic 
MEIS1-AS3 chr2 66653867 66660602 6736 - antisense 
MAP3K14-AS1 chr17 43325292 43345997 20706 + antisense 
MAP3K14 chr17 43340488 43394414 53927 - processed_transcript 
LMCD1-AS1 chr3 7994492 8653610 7E+05 - antisense 
LINC01011 chr6 2988201 2991407 3207 + lincRNA 
LINC01004 chr7 104590762 104653491 62730 - antisense 
 8 
LINC00974 chr17 39705858 39710747 4890 - lincRNA 
LINC00938 chr12 46119510 46121558 2049 - lincRNA 
LINC00899 chr22 46435787 46440733 4947 - processed_transcript 
LINC00857 chr10 81967466 81979413 11948 + lincRNA 
LINC00847 chr5 180257957 180262726 4770 + lincRNA 
LINC00638 chr14 105287538 105290055 2518 + lincRNA 
LINC00605 chr14 103653558 103655365 1808 - lincRNA 
LINC00518 chr6 10429488 10435107 5620 - lincRNA 
LINC00511 chr17 70319264 70636611 3E+05 - lincRNA 
LINC00336 chr6 33553883 33561115 7233 - antisense 
LINC00324 chr17 8123960 8127361 3402 - lincRNA 
LINC00319 chr21 44866481 44873773 7293 + lincRNA 
LINC00313 chr21 44881974 44899414 17441 - lincRNA 
LINC00176 chr20 62665697 62671315 5619 + lincRNA 
LINC00163 chr21 46409779 46414001 4223 - lincRNA 
LINC00114 chr21 40110945 40119384 8440 - lincRNA 
LINC00111 chr21 43099341 43117496 18156 + lincRNA 
KRTAP5-AS1 chr11 1592583 1620414 27832 + antisense 
ITGB2-AS1 chr21 46340966 46349593 8628 + antisense 
HPN-AS1 chr19 35549963 35597208 47246 - antisense 
HOXB-AS3 chr17 46626992 46683776 56785 + antisense 
HOXB-AS1 chr17 46620913 46628610 7698 + antisense 
HCG11 chr6 26522076 26526807 4732 + lincRNA 
GATA6-AS1 chr18 19746859 19748929 2071 - lincRNA 
FAM13A-AS1 chr4 89630940 89651254 20315 + antisense 
ENO1-AS1 chr1 8938894 8939953 1060 + antisense 
EMX2OS chr10 119232726 119304579 71854 - antisense 
EGOT chr3 4790876 4793274 2399 - lincRNA 
DLGAP1-AS1 chr18 3593730 3598350 4621 + antisense 
CYP1B1-AS1 chr2 38302791 38408997 1E+05 + antisense 
CSNK1G2-AS1 chr19 1952530 1954585 2056 - antisense 
CPEB2-AS1 chr4 14911585 15003669 92085 - lincRNA 
COL18A1-AS2 chr21 46827301 46829980 2680 - antisense 
COL18A1-AS1 chr21 46839631 46844985 5355 - antisense 
CDKN2B-AS1 chr9 21994777 22121096 1E+05 + antisense 
CD27-AS1 chr12 6548167 6560733 12567 - antisense 
BAIAP2-AS1 chr17 79002933 79008501 5569 - lincRNA 
ASB16-AS1 chr17 42253341 42264085 10745 - antisense 
ARHGAP26-AS1 chr5 142239169 142248487 9319 - antisense 
AGAP11 chr10 88752163 88769960 17798 + processed_transcript 
ACTN1-AS1 chr14 69446399 69454180 7782 + antisense 
ABO chr9 136125788 136150617 24830 - processed_transcript 
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Table S3. Differentially expressed proteins caused by disruption of UCA1, Related to Figure 4A 
Protein OVCA429-1 
OVCA
429-2 
Contr
ol-1 
Contr
ol-2 
Contr
ol-3 
UCA1 
KO1-1 
UCA1 
KO1-2 
UCA1 
KO1-3 
UCA1 
KO2-1 
UCA1 
KO2-2 
Ratio 
(KO/
WT) 
T test 
PEA-15-R-V_GBL1116480 1.04 1.03 1.06 1.07 1.09 0.94 0.91 0.97 0.97 0.97 0.90 9.10E-05 
UGT1A-M-V_GBL1116415 1.12 1.11 1.05 1.11 1.13 0.93 0.91 0.89 0.97 0.98 0.85 1.66E-04 
c-Met_pY1234_Y1235-R-
V_GBL1115572 1.23 1.18 1.18 1.23 1.16 0.92 0.85 0.78 0.95 0.89 0.74 1.67E-04 
Caveolin-1-R-V_GBL1115521 1.14 1.16 1.18 1.15 1.28 0.78 0.75 0.72 0.85 0.83 0.66 2.07E-04 
H2AX_pS139-R-V_GBL1116473 1.02 1.03 1.04 1.02 1.00 0.97 0.98 0.98 0.97 0.98 0.95 9.14E-04 
PCNA-M-C_GBL1116373 1.03 1.06 1.07 1.07 1.01 0.92 0.86 0.87 0.90 0.95 0.86 0.01 
LDHA-R-C_GBL1115596 1.14 1.18 1.18 1.28 1.42 0.85 0.54 0.64 1.08 0.82 0.63 0.01 
Rb_pS807_S811-R-
V_GBL1115559 1.25 1.22 1.09 1.20 1.09 0.93 0.86 0.87 1.09 0.93 0.80 0.01 
Bcl2A1-R-V_GBL1116330 1.11 1.04 1.11 1.00 1.03 0.98 0.93 0.95 0.95 0.96 0.90 0.01 
MSH6-R-C_GBL1115609 1.08 1.07 1.11 1.10 1.14 0.90 0.78 0.82 1.04 0.93 0.81 0.01 
Cyclin-B1-R-V_GBL1115524 1.07 1.10 1.05 1.07 1.03 1.01 1.00 0.95 0.88 0.83 0.88 0.01 
PYGM-M-C_GBL1116395 1.07 1.09 1.01 1.08 1.10 0.98 0.86 0.86 1.02 0.90 0.86 0.01 
Myosin-11-R-V_GBL1115630 1.01 1.18 0.92 1.27 1.28 0.85 0.50 0.54 1.05 0.79 0.66 0.01 
CD49b-M-V_GBL1116425 0.97 0.99 0.95 1.12 1.04 0.94 0.84 0.88 1.04 0.96 0.92 0.02 
Lck-R-V_GBL1115538 1.46 1.49 1.03 1.43 1.45 0.73 0.67 0.66 1.32 1.02 0.64 0.02 
EGFR_pY1173-R-V_GBL1115526 1.10 1.07 1.10 0.98 1.02 0.93 0.96 0.90 0.95 0.93 0.89 0.02 
Gys_pS641-R-V_GBL1115603 1.08 1.12 1.05 1.05 1.03 0.95 0.97 0.90 1.03 0.96 0.90 0.02 
RBM15-R-V_GBL1115629 1.09 1.03 1.00 1.03 1.05 0.97 0.84 0.81 1.01 0.97 0.89 0.02 
PMS2-R-V_GBL1116324 1.17 1.18 1.04 1.07 1.09 0.96 0.87 0.87 1.05 0.95 0.84 0.02 
Src_pY416-R-C_GBL1116447 1.00 1.01 1.01 1.03 1.06 0.96 1.00 0.97 0.94 1.01 0.95 0.02 
Transglutaminase-M-
V_GBL1116383 0.87 0.96 1.11 1.05 1.09 0.51 0.55 0.56 0.95 0.96 0.69 0.02 
XPA-M-V_GBL1116419 1.09 1.15 0.99 1.07 1.01 0.92 0.99 0.94 0.96 0.99 0.90 0.02 
RPA32-T-C_GBL1116471 1.06 1.03 0.98 1.04 1.10 0.92 0.88 0.85 1.03 1.04 0.91 0.02 
Ets-1-R-V_GBL1116361 1.24 1.18 1.36 1.01 1.24 0.95 0.69 0.73 0.99 0.90 0.70 0.03 
Axl-R-V_GBL1116474 1.47 1.09 1.14 1.08 1.13 0.83 0.89 0.91 0.88 0.93 0.75 0.03 
UQCRC2-M-C_GBL1116412 1.04 1.04 1.01 1.00 1.04 1.02 0.93 0.94 0.96 1.01 0.95 0.03 
ERCC5-R-C_GBL1116336 1.00 1.00 1.08 1.07 1.06 0.99 0.96 0.94 0.93 0.98 0.92 0.04 
S6_pS240_S244-R-V_GBL1115562 1.19 1.12 0.99 1.12 1.07 0.96 0.79 0.84 1.12 0.94 0.85 0.04 
Glutaminase-R-C_GBL1116346 0.98 0.95 1.07 1.05 1.06 0.87 0.81 0.80 1.02 0.98 0.88 0.04 
Rad50-M-V_GBL1116385 1.05 1.05 1.08 0.99 1.01 1.01 1.00 0.97 0.94 1.00 0.95 0.04 
eEF2-R-C_GBL1115607 1.05 1.08 1.15 1.07 1.23 0.87 0.43 0.46 1.04 0.83 0.65 0.04 
ERCC1-M-V_GBL1116435 1.03 1.08 0.96 1.03 1.02 0.93 0.93 0.93 1.00 0.99 0.93 0.04 
 10 
Dvl3-R-V_GBL1116454 1.02 1.03 0.91 1.04 1.05 0.99 0.91 0.90 0.99 0.96 0.94 0.04 
Myosin-IIa_pS1943-R-
V_GBL1115635 1.23 1.43 1.02 1.28 1.50 0.82 0.17 0.26 1.30 0.90 0.54 0.05 
FAK-R-C_GBL1115530 1.11 1.08 1.03 1.06 1.09 1.08 0.89 0.96 1.04 0.94 0.91 0.05 
Chk1_pS296-R-V_GBL1116335 1.11 1.11 1.03 1.00 0.99 1.04 1.09 1.03 0.95 0.96 0.97 0.05 
p53-R-C_GBL1115545 0.88 0.93 0.91 0.89 0.91 1.01 1.03 1.03 0.99 1.04 1.13 1.89E-04 
NDRG1_pT346-R-V_GBL1116491 0.84 0.90 0.82 0.84 0.81 1.20 1.22 1.25 1.07 1.18 1.41 4.42E-04 
Gab2-R-V_GBL1115594 0.88 0.91 0.82 0.80 0.80 1.06 1.05 1.05 0.93 0.99 1.20 7.12E-04 
PDK1_pS241-R-V_GBL1115550 0.93 0.88 0.94 0.87 0.92 1.14 1.08 1.05 1.02 1.04 1.17 1.49E-03 
Claudin-7-R-V_GBL1115586 0.85 0.86 0.82 0.99 0.98 1.06 1.32 1.16 1.45 1.32 1.40 1.52E-03 
Tuberin_pT1462-R-
V_GBL1116448 0.91 0.92 0.80 0.84 0.85 1.01 1.04 1.02 0.96 0.99 1.16 2.48E-03 
INPP4b-R-V_GBL1115611 0.90 0.90 0.96 0.96 0.96 1.13 1.03 1.07 1.10 1.09 1.16 2.57E-03 
p27_pT198-R-V_GBL1115587 0.97 0.95 1.00 0.94 0.95 1.01 1.03 1.04 0.99 0.98 1.05 2.92E-03 
ACVRL1-R-C_GBL1116458 0.98 0.98 0.96 0.95 1.01 1.04 1.02 0.99 0.97 1.04 1.04 3.58E-03 
Pdcd4-R-C_GBL1115583 0.85 0.89 0.88 0.93 0.97 1.02 1.07 1.09 1.04 1.04 1.17 4.02E-03 
Tuberin-R-V_GBL1115566 0.96 0.95 0.88 0.98 0.97 1.14 1.04 1.02 1.08 1.04 1.12 4.51E-03 
Caspase-3-R-C_GBL1115519 0.93 0.91 0.96 0.92 0.91 1.02 1.05 1.04 0.98 0.96 1.09 0.01 
Tyro3-R-V_GBL1116457 0.95 0.96 0.93 0.92 0.93 1.04 1.06 1.00 0.99 1.11 1.11 0.01 
c-Abl-R-V_GBL1116347 1.00 0.99 1.04 0.99 0.95 1.04 1.02 1.05 1.02 0.99 1.03 0.01 
ER-R-V_GBL1116352 0.91 0.89 0.95 0.91 0.91 1.10 1.04 1.06 0.97 1.11 1.15 0.01 
HER2-M-V_GBL1116406 0.92 0.92 0.93 0.91 0.95 1.04 1.06 1.03 0.94 1.06 1.11 0.01 
A-Raf-R-V_GBL1116314 0.98 0.95 0.92 0.92 0.89 1.02 1.04 1.08 1.01 0.97 1.10 0.01 
MMP2-R-V_GBL1115540 0.91 0.93 0.95 0.92 0.91 1.06 1.03 1.03 0.95 1.00 1.10 0.01 
D-alpha-Tubulin-R-
V_GBL1116339 1.01 0.98 0.94 0.91 0.93 1.14 1.05 1.04 0.96 0.97 1.08 0.01 
CXCR4-R-C_GBL1116362 0.94 0.95 0.96 0.94 0.90 1.02 1.03 1.03 1.01 1.09 1.11 0.01 
Cyclophilin-F-M-V_GBL1116413 0.92 0.97 0.91 0.93 0.90 1.03 1.02 1.04 0.96 1.01 1.09 0.01 
P-Cadherin-R-C_GBL1116446 0.97 1.00 0.91 0.95 0.92 1.05 1.04 0.94 1.03 1.05 1.08 0.02 
PDGFR-beta-R-V_GBL1116319 1.00 0.94 0.96 0.94 0.86 1.01 1.06 1.06 1.00 0.95 1.08 0.02 
MEK2-R-V_GBL1116323 1.03 1.00 0.98 0.95 0.95 1.13 1.05 1.01 1.07 1.10 1.09 0.02 
TFAM-R-V_GBL1116333 0.88 0.95 0.89 0.89 0.91 0.98 1.13 1.10 0.95 0.97 1.13 0.02 
IGFBP5-G-C_GBL1116469 0.93 0.91 0.93 0.94 0.91 0.98 1.06 1.01 0.97 0.99 1.08 0.02 
Bad_pS112-R-V_GBL1115511 1.00 0.88 1.01 0.89 0.94 1.14 1.11 1.06 1.06 0.99 1.14 0.02 
Notch3-R-C_GBL1116354 0.89 0.88 0.99 0.94 0.97 1.02 1.06 1.04 1.00 1.03 1.10 0.02 
mTOR_pS2448-R-C_GBL1115542 0.99 0.99 0.91 1.04 0.98 1.08 1.01 1.01 1.06 1.06 1.06 0.02 
eIF4E-R-V_GBL1115571 0.88 0.92 1.01 0.95 0.98 0.98 0.98 1.05 0.99 1.00 1.05 0.02 
MDM2_pS166-R-V_GBL1116306 0.96 0.94 1.00 1.01 1.01 1.09 1.02 1.01 1.08 1.07 1.07 0.02 
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Notch1-R-V_GBL1115610 0.99 1.02 0.91 0.89 0.91 1.08 1.03 1.03 1.08 1.03 1.11 0.03 
ATM-R-V_GBL1116337 0.91 0.89 0.79 0.92 0.87 1.05 1.12 1.11 0.94 1.00 1.19 0.03 
Rictor_pT1135-R-V_GBL1115627 0.93 0.92 0.90 0.99 0.91 1.04 1.03 1.03 0.98 0.98 1.09 0.03 
Rictor-R-C_GBL1115626 0.95 0.94 0.92 0.97 0.94 1.03 1.03 1.04 0.97 0.98 1.07 0.04 
Src-M-V_GBL1116378 1.01 0.93 0.93 0.88 0.81 1.04 1.13 0.99 1.02 1.11 1.16 0.04 
YAP_pS127-R-E_GBL1115578 0.83 0.89 0.99 0.96 1.00 1.41 1.12 1.11 1.37 1.08 1.30 0.04 
Puma-R-C_GBL1116329 0.89 0.92 0.91 0.91 0.90 1.01 1.02 1.04 1.30 1.01 1.18 0.04 
Pdcd-1L1-G-C_GBL1116468 0.91 0.96 0.81 0.80 0.97 0.96 1.04 1.02 1.00 0.99 1.13 0.05 
CD29-M-V_GBL1116426 0.89 0.93 0.96 0.95 0.95 0.95 1.06 1.02 0.94 1.02 1.07 0.05 
The differentially expressed proteins with P≤0.05 are shown. 
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Table S4. iRAP antisense DNA probe sequences, Related to Figure 5 
Target Sequence 
Access # 
Probe Sequence Length Start End Gene ID 
Gene 
Name 
Note 
NR_015379 GGACTCATTGTCCAGAAGAA 20 6 25 652995 UCA1 Odd 
NR_015379 GTTATCTGTTGTCAGCAGAG 20 61 80 652995 UCA1 Odd 
NR_015379 GAGATAGGAGAGGGGCAGCT 20 124 143 652995 UCA1 Odd 
NR_015379 AAGCATGTCCGTATAGAAGA 20 231 250 652995 UCA1 Odd 
NR_015379 ACGGAATGAGGGCCAGGACA 20 305 324 652995 UCA1 Odd 
NR_015379 GAGGAGATCCGATTTGAAAT 20 381 400 652995 UCA1 Odd 
NR_015379 TGGTCCAAGGGGCTTCTGAG 20 436 455 652995 UCA1 Odd 
NR_015379 CAGCTAGGGTGTCTTCATAT 20 505 524 652995 UCA1 Odd 
NR_015379 AATGACCGGGTAGGGTCTGG 20 579 598 652995 UCA1 Odd 
NR_015379 TGGGCATGGCTTTATTCTGG 20 654 673 652995 UCA1 Odd 
NR_015379 GTTTGTCTGATCGGCTCTCG 20 727 746 652995 UCA1 Odd 
NR_015379 GCATGCTGGGATGGCCATTT 20 813 832 652995 UCA1 Odd 
NR_015379 TTTTATAGGCGGCAGGTCTT 20 875 894 652995 UCA1 Odd 
NR_015379 GACTTTTGACCCAGAGATTT 20 949 968 652995 UCA1 Odd 
NR_015379 GTTGTCCATTTCATGAGAGT 20 1023 1042 652995 UCA1 Odd 
NR_015379 CCCTCTAACAACAAACAACA 20 1111 1130 652995 UCA1 Odd 
NR_015379 CTTTGTCTCCTGGATTAAGC 20 1161 1180 652995 UCA1 Odd 
NR_015379 TCCCATAGGTGTGAGTGGCG 20 1249 1268 652995 UCA1 Odd 
NR_015379 AGCCTTTTGTCCCCATTTTC 20 1320 1339 652995 UCA1 Odd 
NR_015379 CAGTAATCAGGCATATTAGC 20 1399 1418 652995 UCA1 Odd 
NR_015379 GCTAACAAGGTGCCAGTTAG 20 1467 1486 652995 UCA1 Odd 
NR_015379 GACTGCGTGGACACCTTAAA 20 1541 1560 652995 UCA1 Odd 
NR_015379 AGTTCCTTCTGGGGATTACT 20 1606 1625 652995 UCA1 Odd 
NR_015379 GACGGATATGTGCAGGTCAC 20 1724 1743 652995 UCA1 Odd 
NR_015379 CTGTTTCACTTCTTTGTGGT 20 1786 1805 652995 UCA1 Odd 
NR_015379 CATAATGGTGGAATGTCGTA 20 1837 1856 652995 UCA1 Odd 
NR_015379 GATGGGACTCATTGTCCAGG 20 1925 1944 652995 UCA1 Odd 
NR_015379 TAGGCGTGGAAAGTTACAGT 20 2000 2019 652995 UCA1 Odd 
NR_015379 CTGTTAATTCACTTGGGTGC 20 2089 2108 652995 UCA1 Odd 
NR_015379 AGGTTCCTGTCACGCGTGTC 20 2151 2170 652995 UCA1 Odd 
NR_015379 AGGTGCATGGTGGAGAGATG 20 29 48 652995 UCA1 Even 
NR_015379 ATAGGGCTGGGGTAGGCTGT 20 102 121 652995 UCA1 Even 
NR_015379 TGTTAATTCACTTGGGTGCA 20 178 197 652995 UCA1 Even 
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NR_015379 AGATTTTGGCACCAAGTGTC 20 251 270 652995 UCA1 Even 
NR_015379 GGTCGCAGGTGGATCTCTTC 20 325 344 652995 UCA1 Even 
NR_015379 CAGTCTTCAGCCACTAAGCC 20 401 420 652995 UCA1 Even 
NR_015379 CCGTAAGAGTTACCCGAAGC 20 469 488 652995 UCA1 Even 
NR_015379 GTTTGAGGGGTCAGACTTTT 20 542 561 652995 UCA1 Even 
NR_015379 AGAGGGTCCTGCAGATGGAC 20 617 636 652995 UCA1 Even 
NR_015379 GAAGAGGAGAGATCAAGCTG 20 683 702 652995 UCA1 Even 
NR_015379 TGGAAGCATGGCCTTGGCTG 20 778 797 652995 UCA1 Even 
NR_015379 AGGAACGGATGAAGCCTGCT 20 838 857 652995 UCA1 Even 
NR_015379 GAGGATAGGGTCTCAAGATA 20 902 921 652995 UCA1 Even 
NR_015379 ACCATGGGCAAGGATCTGAT 20 991 1010 652995 UCA1 Even 
NR_015379 TGCCAAATATGTGGAACTGG 20 1060 1079 652995 UCA1 Even 
NR_015379 GGCAAAGAGTGAAATGTCCC 20 1134 1153 652995 UCA1 Even 
NR_015379 ATAGTTCTGATTGCAGATCC 20 1210 1229 652995 UCA1 Even 
NR_015379 CCCTGTTGCTAAGCCGATGA 20 1282 1301 652995 UCA1 Even 
NR_015379 GTAGGTGGCGATGAGTTTTT 20 1373 1392 652995 UCA1 Even 
NR_015379 CTTGGAACTGCCCTAATAAA 20 1435 1454 652995 UCA1 Even 
NR_015379 TCTAGTAAGTTTCGGGTCTA 20 1504 1523 652995 UCA1 Even 
NR_015379 GCTGATATTTCTCCGGACTG 20 1578 1597 652995 UCA1 Even 
NR_015379 CTTCAGCTCACAGGCCTGAC 20 1685 1704 652995 UCA1 Even 
NR_015379 CTGCTCCAGACTTCTTGGCT 20 1759 1778 652995 UCA1 Even 
NR_015379 GTGGGTTAATTAGTTAAGGC 20 1815 1834 652995 UCA1 Even 
NR_015379 GATTGATCAGTTGGGGCAGG 20 1886 1905 652995 UCA1 Even 
NR_015379 GTCACAAGGTGCATGGTGGA 20 1950 1969 652995 UCA1 Even 
NR_015379 GGGCAGCTTTATAGGGCTTG 20 2022 2041 652995 UCA1 Even 
NR_015379 CCAATCAGGCTTTGTGTGAG 20 2117 2136 652995 UCA1 Even 
NR_015379 AGGAAAGGAAAACCACATGA 20 2244 2263 652995 UCA1 Even 
NR_004430.2 CTCCCCTGCCAGGTAAGTAT 20 1 20 26871 U1  
All the antisense DNA probes are labeled with biotin at the 3’ end. 
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Table S5. iRAP peptide sequences, Related to Figure 5 
Sequence Proteins Start End U1 UCA1
-Odd1 
UCA1-
Even1 
UCA1
-Odd2 
UCA1-
Even2 
GGGGGQDNGLEGLGNDSR sp|P08621|RU17_HUMAN 394 411 5 2    
ASMQQQQQLASAR sp|Q9Y3Y2|CHTOP_HUMAN 39 51 4     
AVQGGGATPVVGAVQGPVPGMPPMTQAP
R 
sp|P09012|SNRPA_HUMAN 124 152 4 1    
EEEIAALVIDNGSGMCK sp|P63261|ACTG_HUMAN 2 18 3   1  
MMLGTEGGEGFVVK sp|P31943|HNRH1_HUMAN 1 14 3     
NMGGPYGGGNYGPGGSGGSGGYGGR sp|P22626|ROA2_HUMAN 326 350 3 1    
QEMQEVQSSR sp|P22626|ROA2_HUMAN 191 200 3     
QQEVETELK sp|P08621|RU17_HUMAN 79 87 3 2    
RGGADVNIR sp|P08621|RU17_HUMAN 201 209 3 1    
RQQEVETELK sp|P08621|RU17_HUMAN 78 87 3     
STVHEILCK sp|P07355|ANXA2_HUMAN;sp|A
6NMY6|AXA2L_HUMAN 
2 10 3 1  1  
ESTGAQVQVAGDMLPNSTER sp|Q15365|PCBP1_HUMAN;sp|Q1
5366|PCBP2_HUMAN;sp|P57721|
PCBP3_HUMAN 
125 144 2     
SEMTPEELQK sp|P62316|SMD2_HUMAN 9 18 2     
TDYNASVSVPDSSGPER sp|P61978|HNRPK_HUMAN 70 86 2     
DSYVGDEAQSKR sp|P60709|ACTB_HUMAN;sp|P63
267|ACTH_HUMAN;sp|P68133|A
CTS_HUMAN;sp|P68032|ACTC_
HUMAN;sp|P62736|ACTA_HUM
AN;sp|P63261|ACTG_HUMAN 
51 62 2     
VEADRPGK sp|P38159|RBMX_HUMAN;sp|Q9
6E39|RMXL1_HUMAN;sp|O7552
6|RMXL2_HUMAN 
2 9 2     
DSYESYGNSR sp|P38159|RBMX_HUMAN;sp|Q9
6E39|RMXL1_HUM N 
283 292 2     
DGMDNQGGYGSVGR sp|P31 42|HNR 3_HUMAN 288 301 2     
NQGGYGGSSSSSSYGSGR sp|P09651|ROA1_HUMAN 353 370 2    1 
MWDPHNDPNAQGDAFK sp|P08621|RU17_HUMAN 88 103 2     
VNYDTTESKLR sp|P08621|RU17_HUMAN 110 120 2     
MIAGQVLDINLAAEPK sp|P07910|HNRPC_HUMAN 74 89 2     
SLKLQASNVTNKNDPK sp|Q9UKM9|RALY_HUMAN 2 17 1     
HRSCNTDDCPPGSQDFREVQCSEFDSIPFR sp|Q9H324|ATS10_HUMAN 593 622 1     
MSATSVDTQR sp|Q9BYJ9|YTHD1_HUMAN 1 10 1 1 1   
VADLTEQYNEQYGAVR sp|Q9BWF3|RBM4_HUMAN 183 198 1     
EVYQQQQYGSGGR sp|Q99729|ROAA_HUMAN 233 245 1     
EGSIEIDIPVPK sp|Q96RQ3|MCCA_HUMAN 624 635 1     
IIEEAPAPGIK sp|Q96RQ3|MCCA_HUMAN 285 295 1     
YLSSVSSQETQGGPLAPMTGTIEK sp|Q96RQ3|MCCA_HUMAN 636 659 1 1    
TMFENVTR sp|Q96QA5|GSDMA_HUMAN 2 9 1    1 
AGGGPTLQCPPPSSPEK sp|Q96N66|MBOA7_HUMAN 272 288 1     
KIQNDAGVR sp|Q92945|FUBP2_HUMAN;sp|Q9
6I24|FUBP3_HUMAN;sp|Q96AE4
|FUBP1_HUMAN 
347 355 1     
DAFADAVQR sp|Q92945|F BP2_HUMAN 72 80 1     
IGGGIDVPVPR sp|Q92945|FUBP2_HUMAN 321 331 1     
IGQQPQQPGAPPQQDYTK sp|Q92945|FUBP2_HUMAN 629 646 1     
SDYSTGGPPPGPPPPAGGGGGAGGAGGGPP
PGPPGAGDR 
sp|Q92945|FUBP2_HUMAN 2 40 1     
SVSLTGAPESVQK sp|Q92945|FUBP2_HUMAN 191 203 1     
VQISPDSGGLPER sp|Q92945|FUBP2_HUMAN 178 190 1     
APILIATDVASR sp|Q92841|DDX17_HUMAN;sp|P1
7844|DDX5_HUMAN 
469 480 1     
DMVGIAQTGSGK sp|Q92841| DX17_HUMAN 210 221 1     
SSQSSSQQFSGIGR sp|Q92841|DDX17_HUMAN 671 684 1     
VLEEANQAINPK sp|Q92841|DDX17_HUMAN 536 547 1     
EQMEKVEADLTR sp|Q8N8E3|CE112_HUMAN 623 634 1     
QDNTPKR sp|Q8N118|CP4X1_HUMAN 275 281 1    1 
RLASPSEETWITCDNK sp|Q86VB7|C163A_HUMAN 913 928 1     
DLQEQNKK sp|Q5TB80|CE162_HUMAN 733 740 1 1 1 1 1 
VAPDEHPILLTEAPLNPK sp|Q562R1|ACTBL_HUMAN 97 114 1     
GGSYSQAASSDSAQGSDVSLTA sp|Q31612|1B73_HUMAN 342 363 1     
VLVDQTTGLSR sp|Q15717|ELAV1_HUMAN 137 147 1     
QKNKSGETVVLK sp|Q15652|JHD2C_HUMAN 2249 2260 1     
INISEGNCPER sp|Q15365|PCBP1_HUMAN;sp|Q1
5366|PCBP2_HUMAN;sp|P57721|
PCBP3_HUMAN 
47 57 1     
MQSNKTFNLEK sp|Q15233|NONO_HUMAN 1 11 1     
SSSVGSSSSYPISPAVSR sp|Q15149|PLEC_HUMAN 4384 4401 1     
AAAAVQGGR sp|Q15005|SPCS2_HUMAN 2 10 1     
IFVGGLSPDTPEEK sp|Q14103|HNRPD_HUMAN 184 197 1     
SSGGSYRDSYDSYATHNE sp|Q14011|CIRBP_HUMAN 155 172 1     
AASAAAASAAAASAASGSPGPGEGSAGGE
KR 
sp|Q13263|TIF1B_HUMAN 2 32 1     
VLVNDAQK sp|Q13263|TIF1B_HUMAN 312 319 1     
AATASAGAGGIDGKPR sp|Q02978|M2OM_HUMAN 2 17 1     
GDATVSYEDPPTAK sp|Q01844|EWS_HUMAN 411 424 1     
ATVQQLEGR sp|Q01469|FABP5_HUMAN 2 10 1 1    
SSGPTSLFAVTVAPPGAR sp|Q00839|HNRPU_HUMAN 187 204 1     
IQTQPGYANTLR sp|Q00325|MPCP_HUMAN 190 201 1     
MIQVYFPK sp|P82650|RT22_HUMAN 192 199 1     
AADPPAENSSAPEAEQGGAE sp|P67809|YBOX1_HUMAN 305 324 1     
GAEAANVTGPGGVPVQGSK sp|P67809|YBOX1_HUMAN 119 137 1     
GENLVSMTVEGPPPKDTGIAR sp|P63162|RSMN_HUMAN;sp|P14
678|RSMB_HUMAN 
74 94 1     
TITLEVEPSDTIENVK sp|P62987| L40_HUMAN;sp|P629
79|RS27A_HUMAN;sp|P0CG47|U
BB_HUMAN;sp|P0CG48|UBC_H
UMAN 
12 27 1     
AAQGEPQVQFK sp|P62826|RAN_HUMAN 2 12 1     
ECTIEATA sp|P62633|CNBP_HUMAN 170 177 1     
SSNECFKCGR sp|P62633|CNBP_HUMAN 2 11 1     
VAQLEQVYIR sp|P62318|SMD3_HUMAN 55 64 1     
GDNITLLQSVSN sp|P62304|RUXE_HUMAN 81 92 1     
ADIQTER sp|P62280|RS11_HUMAN 2 8 1   1  
EITALAPSTMK sp|P60709|ACTB_HUMAN;sp|P63
267|ACTH_HUMAN;sp|P68133|A
CTS_HUMAN;sp|P68032|ACTC_
HUMAN;sp|P62736|ACTA_HUM
AN;sp|P63261|ACTG_HUMAN 
316 326 1     
AGFAGDDAPR sp|P60709|ACTB_HUMAN;sp|P63
267|ACTH_HUMAN;sp|P68133|A
CTS_HUMAN;sp|P68032|ACTC_
HUMAN;sp|P62736|ACTA_HUM
AN;sp|P0CG39|POTEJ_HUMAN;s
p|Q6S8J3|POTEE_HUMAN;sp|P0
CG38|POTEI_HUMAN;sp|A5A3E
0|POTEF_HUMAN;sp|P63261|AC
19 28 1 1  1 1 
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DDDIAALVVDNGSGMCK sp|P60709|ACTB_HUMAN 2 18 1     
HTGPNSPDTANDGFVR sp|P55795|HNRH2_HUMAN;sp|P3
1943|HNRH1_HUMAN 
99 114 1     
MMLSTEGR sp|P55795|HNRH2_HUMAN 1 8 1     
MLGPEGGEGFVVK sp|P52597|HNRPF_HUMAN 2 14 1     
MGPAMGPALGAGIER sp|P52272|HNRPM_HUMAN 592 606 1     
QGGGGGGGSVPGIER sp|P52272|HNRPM_HUMAN 389 403 1     
SSGSPYGGGYGSGGGSGGYGSR sp|P51991|ROA3_HUMAN 355 376 1     
ALVDGPCTQVR sp|P50914|RL14_HUMAN 36 46 1     
ATTATMATSGSAR sp|P38919|IF4A3_HUMAN 2 14 1  1   
DDGYSTKDSYSSRDYPSSR sp|P38159|RBMX_HUMAN;sp|Q9
6E39|RMXL1_HUMAN 
211 229 1     
DVYLSPR sp|P3815 | BMX_HUMAN;sp|Q9
6E39|RMXL1_HUMAN 
204 210 1     
YDDYSSSR sp|P3815 BMX_HUMAN;sp|Q9
6E39|RMXL1_HUMAN 
310 317 1     
RGPPPPPR sp|P38159|RBMX_HUMAN 94 101 1     
SDLYSSGR sp|P38159|RBMX_HUMAN 332 339 1     
GEATVSFDDPPSAK sp|P35637|FUS_HUMAN;sp|Q928
04|RBP56_HUMAN 
335 348 1     
GLPWSCSADEVQR sp|P31943|HNR 1_HUMAN 17 29 1     
MLGTEGGEGFVVK sp|P31943|HNRH1_HUMAN 2 14 1     
MLGTEGGEGFVVKVR sp|P31943|HNRH1_HUMAN 2 16 1     
STGEAFVQFASK sp|P31942|HNRH3_HUMAN 56 67 1     
DTSSSTVVSTQR sp|P31483|TIA1_HUMAN 90 101 1     
FGQGGAGPVGGQGPR sp|P23246|SFPQ_HUMAN 667 681 1     
MEKTLETVPLER sp|P22626|ROA2_HUMAN 1 12 1     
TLETVPLER sp|P22626|ROA2_HUMAN 4 12 1     
SISLYYTGEK sp|P19338|NUCL_HUMAN 458 467 1     
AGEAPTENPAPPTQQSSAE sp|P16989|YBOX3_HUMAN 354 372 1     
SEAGEATTTTTTTLPQAPTEAAAAAPQDPA
PK 
sp|P16989|YBOX3_HUMAN 2 33 1     
DNEETGFGSGTR sp|P15144|AMPN_HUMAN 924 935 1     
AEAEAQAEELSFPR sp|P11498|PYC_HUMAN 929 942 1     
ALAVSDLNR sp|P11498|PYC_HUMAN 1062 1070 1     
SKSESPKEPEQLR sp|P09651|ROA1_HUMAN 2 14 1     
DGGAWGTEQR sp|P09382|LEG1_HUMAN 65 74 1    1 
EVSSATNALR sp|P09012|SNRPA_HUMAN 61 70 1     
IQYAKTDSDIIAK sp|P09012|SNRPA_HUMAN 84 96 1     
KAVQGGGATPVVGAVQGPVPGMPPMTQA
PR 
sp|P09012|SNRPA_HUMAN 123 152 1  1 1  
TDSDIIAK sp|P09012|SNRPA_HUMAN 89 96 1     
AETREERMER sp|P08621|RU17_HUMAN 60 69 1     
DPIPYLPPLEK sp|P08621|RU17_HUMAN 17 27 1     
GGADVNIR sp|P08621|RU17_HUMAN 202 209 1     
GSERGRDEAR sp|P08621|RU17_HUMAN 384 393 1     
IHMVYSK sp|P08621|RU17_HUMAN 132 138 1     
KEELRGGGGDMAEPSEAGDAPPDDGPPGE
LGPDGPDGPEEK 
sp|P08621|RU17_HUMAN 306 346 1 1    
VLVDVER sp|P08621|RU17_HUMAN 174 180 1 1    
AAVAGEDGR sp|P07910|HNRPC_HUMAN;sp|P0
DMR1|HNRC4_HUMAN;sp|O608
12|HNRC1_HUMAN;sp|B7ZW38|
HNRC3_HUMAN;sp|B2RXH8|HN
RC2_HUMAN 
65 73 1     
ASNVTNKTDPR sp|P07910|HNRPC_HUMAN 2 12 1     
VPPPPPIAR sp|P07910|HNRPC_HUMAN 143 151 1     
AMGEQAVALAR sp|P05165|PCCA_HUMAN 315 325 1     
MADALDNYVIR sp|P05165|PCCA_HUMAN 466 476 1     
MADEAVCVGPAPTSK sp|P05165|PCCA_HUMAN 105 119 1     
VVEEAPSIFLDAETR sp|P05165|PCCA_HUMAN 299 313 1     
SGAQASSTPLSPTR sp|P02545|LMNA_HUMAN 12 25 1     
MEDSASASLSSAAATGTSTSTPAAPTAR sp|O76021|RL1D1_HUMAN 1 28 1     
TGYTLDVTTGQR sp|O60506|HNRPQ_HUMAN;sp|O
43390|HNRPR_HUMAN 
131 142 1     
MEKENQKLEASR sp|O60343|TBCD4_HUMAN 856 867 1     
PAASITSKPATLTTTSATSK sp|O43670|ZN207_HUMAN 343 362 1     
NDNQETAAMKPENLKK sp|A2A2Z9|AN18B_HUMAN 266 281 1     
QMEEELLFLK tr|Q8WYG7|Q8WYG7_HUMAN 12 21     1 
STILQQQFNR sp|Q9Y4G6|TLN2_HUMAN 432 441  1 1   
QTDAQSASSPKK sp|Q9Y3R0|GRIP1_HUMAN 754 765   1   
GVLQQGAGALGSSAQGVK sp|Q9H8X9|ZDH11_HUMAN 297 314  1    
GGGEQETQELASK sp|Q96QR8|PURB_HUMAN 25 37  1    
SSGQMAQKFSFSK sp|Q96Q89|KI20B_HUMAN 105 117    1  
MKQKQEVMFQSR sp|Q96LM1|CL037_HUMAN 1 12     1 
DGAILCQPYITNGSLSLGVCGPQGR sp|Q96BF3|TMIG2_HUMAN 62 86     1 
STEPKMETMR sp|Q8WTQ4|CP078_HUMAN 197 206    1  
SLQKEGFWPEAFSEVAEK sp|Q8N9N8|EIF1A_HUMAN 95 112  1 1   
DQAEQWLR sp|Q8N4X5|AF1L2_HUMAN 257 264  1 1   
FYEMYLLINK sp|Q8IZJ1|UNC5B_HUMAN 577 586  1    
NSLSSIMKNKDK sp|Q8IY51|TIGD4_HUMAN 51 62    1  
KNDQALQLTQMDKMHK sp|Q86Z20|CC125_HUMAN 337 352    1  
GSGSGQSPSYGR sp|Q86YZ3|HORN_HUMAN;CON
__Q86YZ3 
897 908     1 
HGSSSGSSSR sp|Q86YZ3|HORN_HUMAN;CON
__Q86YZ3 
2149 2158    1 1 
QGSSAGSSSSYGQHGSGSR sp|Q86YZ3|HORN_HUMAN;CON
__Q86YZ3 
507 525    1  
YGQQGSGSGQSPSR sp|Q86YZ3|HORN_HUMAN;CON
__Q86YZ3 
649 662     1 
FEVNAKFLGVDMER sp|Q86VI3|IQGA3_HUMAN 1575 1588  1 1   
DVDAAYVSK sp|Q7Z794|K2C1B_HUMAN;CON
__Q7Z794 
274 282    1 1 
VTVQTDDSNK sp|Q6ZP68|ATPUN_HUMAN 105 114     1 
SGTNNHVTVAIEN sp|Q5W0Z9|ZDH20_HUMAN 353 365    1 1 
QESTSKADLNCSKNK sp|Q5W0B1|RN219_HUMAN 328 342   1   
IQSSQPMSLK sp|Q5U4N7|GDF5O_HUMAN 2 11    1  
IEISSPCCPR sp|Q5T749|KPRP_HUMAN 327 336   1 1 1 
CQEEFWIR sp|Q5FWF4|ZRAB3_HUMAN 940 947    1 1 
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FSNSSSSNEFSK sp|Q5D862|FILA2_HUMAN;CON
__Q5D862 
404 415     1 
AGSLQLSSMSAGNSSLR sp|Q53SF7|COBL1_HUMAN 380 396   1 1  
IQKEEEEILMANKR sp|Q4VCS5|AMOT_HUMAN 727 740  1 1  1 
DMLMQER sp|Q3ZCV2|CA177_HUMAN 391 397   1 1 1 
MEPIYPFARPQMNTR sp|Q15468|STIL_HUMAN 1 15  1 1   
ERDAALK sp|Q14980|NUMA1_HUMAN 598 604     1 
NEWRMITAMNTIR sp|Q14145|KEAP1_HUMAN 495 507  1    
KPEYDLEEDDQEVLK sp|Q13416|ORC2_HUMAN 52 66  1    
MQLDNPSK sp|Q13085|ACACA_HUMAN 818 825  1    
NVLLNNSEK sp|Q08J23|NSUN2_HUMAN 569 577  1 1   
ENAGEDPGLAR sp|P81605|DCD_HUMAN 43 53  1 1  1 
DSYVGDEAQSK sp|P60709|ACTB_HUMAN;sp|P63
267|ACTH_HUMAN;sp|P68133|A
CTS_HUMAN;sp|P68032|ACTC_
HUMAN;sp|P62736|ACTA_HUM
AN;sp|P63261|ACTG_HUMAN 
51 61    1 1 
MNALDLNMKTK sp|P30519|HMOX2_HUMAN 206 216   1   
GGGGNFGPGPGSNFR sp|P22626|ROA2_HUMAN 214 228  1 1   
NLKNSQMCQK sp|P21439|MDR3_HUMAN 670 679    1  
NMLSQVNYRVPNMR sp|P19174|PLCG1_HUMAN 179 192  1 1   
RQQLNEMLK sp|P11532|DMD_HUMAN 2572 2580    1  
KNSYMNPEKK sp|P08473|NEP_HUMAN 737 746   1   
AQGYSGLSVK sp|P07996|TSP1_HUMAN;CON__
Q28194 
1055 1064    1  
GPDPSSPAFR sp|P07996|TSP1_HUMAN;CON__
Q28194 
51 60    1  
GTSQNDPNWVVR sp|P07996|TSP1_HUMAN;CON__
Q28194 
969 980    1  
SSPVVIDASTAIDAPSNLR sp|P02751|FINC_HUMAN 1892 1910    1 1 
TSLDEALQWR sp|O15539|RGS5_HUMAN 53 62  1 1   
VAASIGNAQK sp|O00151|PDLI1_HUMAN 247 256  1    
The numbers under each probe are the peptide hits obtained by mass spectrometry for iRAP protein samples. 
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Table S6. Antibody information used in this study, Related to Figure 4, 5, & 6 
 
 
 
 
  
ANTIBODY SOURCE IDENTIFIER NOTE 
β-tubulin Sigma Aldrich Cat#T8328, RRID: AB_1844090 1:2,000 
U1-70k EMD Millipore Cat#05-1588, RRID: AB_10805959 1:1,000 
AMOT Bethyl laboratories Cat#A303-305A, RRID:  AB_10951678 1:500 
AXL R&D Systems Cat#AF-154, RRID:  AB_354852  1:1,000 
CYR61 Cell Signaling Technology Cat#14479S, RRID: N/A  1:1,000 
CTGF Abcam Cat# ab6992, RRID:  AB_305688 1:1,000 
YAP Santa Cruz Cat#sc-15407, RRID:  AB_2273277  1:100-1,000, WB 
YAP Cell Signaling Technology Cat#4912S, RRID: AB_2218911 IP 
YAP (phosphoS127) Abcam Cat#ab76252, RRID:  AB_1524578  1:1,000 
Phospho-LATS1 Cell Signaling Technology Cat#8654S, RRID: AB_10971635  1:100 
LATS1 Cell Signaling Technology Cat#3477T, RRID: AB_2133513  1:500 
GFP Santa Cruz Cat#sc-9996, RRID:  AB_627695 1:2,000 
GAPDH Fitzgerald Antibody Cat#10R-G109A, RRID: AB_1285808  1:2,000 
β-actin Santa Cruz Cat#sc-47778, RRID:  AB_626632  1:2,000 
  Rabbit IgG Thermo Fisher Scientific Cat#10500C, RRID: AB_2532981 IP 
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Transparent Methods 
Cell Culture. FTSEC33 and FTSEC246 cells were grown in DMEM/F12 media supplied with 10% FBS 
(HyClone, catalogue number: SH3007103) and L-glutamine. OSEC4 and OSEC11 were cultured in NOSE-CM 
media consisting of MCDB105: Medium 199 (1:1), 15% FBS, 10 ng/mL epidermal growth factor (Sigma 
Aldrich, catalogue number: E9644-2MG), 0.5 mg/mL hydrocortisone (Sigma Aldrich, catalogue number: 
H0888), 5 mg/mL insulin (Sigma, catalogue number: I1882-100MG), and 34 mg protein/mL bovine pituitary 
extract (Thermo Fisher Scientific, catalogue number: 13028014). CaOV3 cells were grown in RPMI1640 
supplied with 10% FBS and L-glutamine. OVCA429 cells were cultured in EMEM supplied with 10% FBS, L-
glutamine, sodium pyruvate (Lonza, catalogue number: 13-115E), and nonessential amino acids (Lonza, 
catalogue number: 13-114E). UWB1.289 cells were grown in mammary epithelial growth medium (MEGM): 
RPMI1640 (1:1) supplied with 3% FBS. HEK293T cells were cultured in DMEM supplied with 10% FBS. 
H3K27ac ChIP-Seq and Super-enhancer Identification. H3K27ac ChIP-Seq and data analysis for primary 
ovarian cancer specimens were performed as described previously (Lawrenson et al., 2018). H3K27ac ChIP-
Seq data for FTSEC33, FTSEC246, OSEC4, and OSEC11 are publicly available (Coetzee et al., 2015). The 
AQUAS pipeline (https://github.com/kundajelab/chipseq_pipeline) was used to processed ChIP-Seq data. Reads 
were aligned to the reference human genome (hg19), filtered by read quality and duplicate reads removed. 
MACS2 (https://pypi.python.org/pypi/MACS2) was used for peak calling. For the cell lines, two technical 
replicates were generated and the final peaks were obtained using a naive overlap approach, where the peaks are 
included if they overlap more than 50% between the two technical replicates. After alignment, homer 
(http://homer.ucsd.edu/homer/) was used to identify super-enhancers, using a super slope parameter of 2 and a 
minimum distance of ten thousand base pairs. For defining a set of high-grade serous ovarian cancer super-
enhancers, we selected super-enhancers that were called in at least two high-grade serous ovarian cancer 
samples. For the FTSEC and OSEC sets of super-enhancers, super-enhancers were called individually in each 
technical replicate, then all the super-enhancers that overlapped both technical replicates within the same cell 
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line were selected to get the union set. To identify super-enhancer-associated lncRNAs, we directly overlapped 
the expressed lncRNAs with super-enhancers in high-grade serous EOC.  
Survival and Super-enhancer-association Analysis. We used the superpc R package to perform the survival 
analysis using data from profiling of high-grade serous EOCs performed by TCGA (Cancer Genome Atlas 
Research, 2011). As training set 80% of the samples were randomly selected (377 samples) and the other 20% 
(77 samples) were used as the test set. Information about vital status was obtained from TCGA. We defined the 
threshold parameter as 1.4, n.components=3 and prediction.type="continuous". The significant genes were 
obtained in order of decreasing importance score. Super-enhancer domains in each cell line were identified 
using published procedures (Lovén et al., 2013; Whyte et al., 2013). To associate super-enhancers to lncRNAs 
we used the GenomicFeatures package (version 1.28.4) to manipulate the enhancer and lncRNAs genomic 
annotations. Gene coordinates were obtained using TxDb.Hsapiens.UCSC.hg19.knownGene (version 3.2.2) and 
org.Hs.eg.db (version 3.4.1) libraries.  
RNA-Seq Data Generation and Analysis. Primary ovarian cancer specimens were homogenized and total 
RNA was extracted using TRIzol LS (Thermo Fisher Scientific, catalogue number: 10296028). Ribosomal 
RNA (rRNA) was depleted using RiboMinus Transcriptome Isolation Kit (Thermo Fischer Scientific, catalogue 
number: K155002). Poly (A)+ RNA was then isolated using Dynabeads Oligo (dT)25 (Thermo Fischer 
Scientific, catalogue number: 61002). Twenty nanograms rRNA-poly (A)+ RNA was used to prepare each 
RNA-Seq library. External RNA Controls Consortium (ERCC) spike-ins (Thermo Fischer Scientific, catalogue 
number: 4456740) were added as control for normalization of the samples. Strand-specific RNA-Seq libraries 
were constructed using the NEBNext Ultra Directional RNA Library Prep Kit (NEB, catalogue number: 
E7420). The resulting library concentrations were quantified using the Nanodrop. Libraries were sequenced to 
generate paired-end 75 bp reads on NextSeq 500 platform (Illumina) in high output running mode. Sequencing 
was performed at the Molecular Genomics Core facility at the University of Southern California. RNA-Seq data 
were analyzed using Partek Flow and Partek Genomics Suite software after mapping reads to reference lncRNA 
gene mode (Gencode V16) with Tophat2. 
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Data Availability. H3K27ac ChIP-Seq data for normal precursor cells and primary tumors as well as RNA-Seq 
data for primary tumors have been deposited in the Gene Expression Omnibus database (GEO: GSE121103). 
(+)-JQ1 treatment of the ovarian cancer cells. CaOV3 or UWB1.289 cells were treated with 10 nM (+)-JQ1 
(Tocris, catalogue number: 4499) or an equal volume of DMSO (Sigma Aldrich, catalogue number: D2650) for 
16 h before harvesting for RNA extraction.  
Reverse transcription and real time quantitative PCR (RT-qPCR). RNA was extracted using TRIzol LS 
(Thermo Fisher Scientific, catalogue number: 10296028). M-MLV reverse transcriptase (Promega, catalogue 
number: M5301) and random hexamers (Promega, catalogue number: C1181) were used for reverse 
transcription. Gene expression was quantified by RT-qPCR using iQ SYBR Green supermix (Bio-Rad, 
catalogue number: 170-8886). The relative gene expression was calculated using the 2-ΔΔCt method (Schmittgen 
and Livak, 2008). Two hundred and fifty nanograms cDNA was used for RT-qPCR analysis on CFX96 Touch 
Real-Time PCR Detection System (Bio-Rad) using the following primer pairs. UCA1-F: 
5’CTTCTGCATAGGATCTGCAATCAG3’, UCA1-R: TTTTGTCCCCATTTTCCATCATACG. U1-F: 
CCAGGGCGAGGCTTATCCATT, U1-R: GCAGTCCCCCACTACCACAAAT. U6-F: 
GCTTCGGCAGCACATATACTAAAAT, U6-R: CGCTTCACGAATTTGCGTGTCAT. AXL-F: 
GGTGGCTGTGAAGACGATGA, AXL-R: CTCAGATACTCCATGCCACT. CYR61-F: 
AAACCCGGATTTGTGAGGT, CYR61-R: GCTGCATTTCTTGCCCTTT. OR10H1-F: 
CCCAAAAGTCCCCAGTCTCT, OR10H1-R: CTCCTTGTTCCTGAGGCTGA. GAPDH-F: 
TGCCAAATATGATGACATCAAGAA, GAPDH-R: GGAGTGGGTGTCGCTGTTG, 18S-F: 
CAGCCACCCGAGATTGAGCA, 18S-R: TAGTAGCGACGGGCGTGTG, β-actin-F: 
TCACCCACACTGTGCCCATCTACGA, β-actin-R: CAGCGGAACCGCTCATTGCCAATGG. 
CRISPR/Cas9 KO of UCA1. Guide RNAs (gRNAs) were designed using the CRISPR design tool 
(http://crispr.mit.edu/). Two gRNAs were cloned into PX458 (Addgene plasmid number 48138) - UCA1 
promoter: GGTTTCCTTTTAGATGACGG, UCA1 intron: GGCTAGAATATTTGCAGGCG, following the 
methods of the Zhang laboratory (Ran et al., 2013). Target cells were co-transfected with the two gRNAs 
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expressing plasmids or the vector backbone only as a control, using the BioT transfection reagent (Bioland 
Scientific, catalog number: B01-01). Positive cells were isolated using an Aria II flow cytometer (BD 
Biosciences) to sort single cells into 96 well plates. For validation of the deletion, PCR was performed using 
Sequal Prep™ Long PCR Kit with the following primers - Forward: GACACTGCATTGTGTGCGTT, Reverse: 
TCCCTGTTGCTAAGCCGATG. 
Mouse xenografts. All in vivo work was performed with the approval of the USC Institutional Animal Care and 
Use Committee. Ten million cells were injected with 25% Matrigel subcutaneously into female nu/nu mice 
(aged 6-8 weeks). Tumor growth was measured by digital caliper measurement and animals euthanized when 
tumor diameter reached >1.5 cm, or after 8 weeks. 
RPPA. Cells were plated into 6 well plates overnight. Cells were washed with PBS and lysed for 20 minutes in 
buffer containing 1% Triton X-100, 50 mM HEPES, pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 100 
mM NaF, 10 mM Na pyrophosphate, 1 mM Na3VO4, 10% glycerol, plus PhosSTOP Protease Inhibitor Cocktail 
(Roche, catalog number: 4906837001) and Protease Inhibitor Cocktail (Roche, catalog number: 11873580001). 
Insoluble proteins were removed by centrifugation and normalized proteins denatured by boiling in 4× SDS 
sample buffer (40% Glycerol, 8% SDS, 0.25 M Tris-HCl, pH 6.8 plus 10% 2-mercaptoethanol).  
iRAP. Two sets of UCA1 antisense DNA probes with 3’ biotin labels were ordered from siTOOLs Biotech 
GmbH. A U1 antisense probe (Chu et al., 2015)  was included as a positive control. OVCA429 were cultured on 
150 mm tissue culture plates and used at 90% confluency 96 h after seeding. Cells were washed with 10 mL 
ice-cold PBS and crosslinked in the presence of 10 mL ice-cold PBS using a Stratalinker (UV Stratalinker 1800, 
Stratagene) at 254 nm wavelength with 0.8 J/cm2. Cells were collected and centrifuged at 1,000 g for 5 min at 
4 °C. The supernatant was removed and cells used directly for iRAP or snap frozen in liquid nitrogen and stored 
at -80 °C until use. Cells were lysed in Lysis Buffer (10× the mass of pellet, 10 mM Tris-HCl, pH7.0, 50 mM 
EDTA, 1% SDS) containing freshly added PhosSTOP Protease Inhibitor Cocktail (Roche, catalog number: 
4906837001) and Protease Inhibitor Cocktail (Roche, catalog number: 11873580001), PMSF (Sigma Aldrich, 
catalog number: 93482) and Superase-in (Ambion, catalog number: AM2696). Crosslinked cells were lysed 
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using a Covaris E220 evolution Focused-Ultrasonicator at 4 °C, 20% output, 200 burst cycles, for 15 min for 
each 20 million cells in 1 mL lysate buffer. Sonicated samples were centrifuged at 16,000 g for 10 min at 4 °C. 
Cell lysates representing 400 million cells were combined with 2 nM U1 or UCA1-odd/even probe sets in two 
volumes of hybridization buffer (750 mM NaCl, 1% SDS, 50 mM Tris-HCl pH 7.0, 1 mM EDTA, 15% 
formamide, with fresh PMSF, phosphatase inhibitor, proteinase inhibitor cocktail, and Superase-in). 
Hybridization was performed at 37 °C with rotation overnight. RNA-protein complexes were precipitated by 
adding 2 mL Streptavidin Dynabeads M-270 (Thermo Fisher Scientific, catalog number: 65036) for 30 min at 
37 °C. Dynabeads were washed with 2×NaCl and sodium citrate (SSC), 0.5% SDS, and fresh PMSF for 5×5 
min.  
RIP. Twelve microliter Dynabeads Protein A (Thermo Fisher Scientific, catalog number: 10001D) were 
washed with 200 μL HBS (150 mM NaCl, 10 mM HEPES, pH7.5 by KOH and incubated with 2 μg AMOT 
antibody, 2 μg YAP antibody or 2 μg rabbit IgG isotype control in the presence of 80 μL HBS buffer at room 
temperature for 1 h. Eight million CaOV3, OVCA429, or UWB1.289 cells were lysed with 800 μL cell lysis 
buffer (10 mM HEPES, pH7.5 by KOH, 150 mM NaCl, 0.1% NP-40, 5 mM EGTA, supplemented with 1× 
protease inhibitor cocktail and Superase-in) at 4°C for 1 h. Cell debris and insoluble proteins were removed by 
centrifugation at 4°C, 12,000 g for 10 min, and the supernatants were incubated with antibody-conjugated 
Dynabeads at 4°C for 1 h. The Dynabeads were then washed 3 times with wash buffer (150 mM NaCl, 10 mM 
HEPES, pH7.5 by KOH, 0.1% NP-40). Half of the sample was eluted with 12 μL 1×Laemmli sample buffer 
(Bio-Rad, catalog number: 1610747) and used for Western blotting, TRIzol LS was added to the other half 
before proceeding with RNA extraction (Thermo Fisher Scientific, catalog number: 10296028). 
Plasmids. Lenti GFP-AMOT p80 and lenti GFP-AMOT p130 were gifts from Dr. Kun-Liang Guan (Addgene 
plasmid numbers 32830 & 32828). To generate a UCA1 overexpression plasmid, the full cDNA sequence for 
UCA1 was purchased from Genewiz and cloned into the LeGO-iT vector. LeGO-iT was a gift from Dr. Boris 
Fehse (Addgene plasmid number 27361). Lentiviral particles were produced from co-transfecting HEK293T 
cells with LeGO-iT+UCA1, Lenti GFP-AMOT p80, or Lenti GFP-AMOT p130 together with lentiviral 
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packaging plasmids pMD2.G and psPAX2 (Gifts from Dr. Didier Trono, Addgene plasmid numbers 12259 & 
12260). LeGO-iT has an IRES-tdTomato marker that was used for flow cytometric selection on Aria II cell 
sorter (BD Biosciences) after transduction. 
Transfection. Pooled siRNAs targeting human UCA1 (Dharmacon, catalog number: R-188002-00-0005), 
AMOT (Dharmacon, catalog number: L-015417-01-0005), YAP (Dharmacon, catalog number: L-012200-00-
0005) or non-targeting scramble controls (Dharmacon, catalog number: D-001810-01-20) were transfected into 
CaOV3, UWB1.289, or OVCA429 cells using Lipofectamine RNAiMAX transfection reagent (Thermo Fisher 
Scientific, catalog number: 13778075), DharmaFECT 3 (Dharmacon, catalog number: T-2003-03), or 
DharmaFECT 1 transfection reagent (Dharmacon, catalog number :T-2001-03), respectively.   
Cellular fractionation. Cells were fractionated as previously described (Bahn et al., 2015) with some 
modifications. Six million OVCA429 cells were treated with the plasma membrane lysis buffer (10 mM Tris-
HCl, pH 7.5, 0.15% Nonidet P-40, 150 mM NaCl) on ice for 5 min after homogenization by flicking. For 
CaOV3 and UWB1.289 cells, six million cells were lysed for 4 min with lysis buffer and for OSEC4C2 cells, 
eight million cells were treated with lysis buffer for 2 min. Centrifuge at 15,000 g for 10 min at 4°C after 
loading the lysate onto 24% sucrose cushion (24% RNase-free sucrose in plasma membrane lysis buffer) using 
large orifice tips. The supernatant (cytoplasmic fraction) was retained after centrifugation, and the pellet 
(nuclear fraction) was washed with 1×PBS/1 mM EDTA and resuspended in 200 μL of 1×PBS/1 mM EDTA.  
Western Blotting. Protein samples were run on 4-20% gradient precast protein gel (Bio-Rad, catalogue 
number: 456-1096) and transferred onto PVDF membrane (Bio-Rad, catalogue number: 1704157). After 1 h 
blocking, membranes were incubated with corresponding antibody at 4°C overnight. Membranes were washed 
three times with Tris-buffered saline containing 0.5% Tween 20 (TBST) before incubating with HRP-
conjugated secondary antibody or Clean-Blot IP detection reagent (Thermo Fisher Scientific, catalogue number: 
21230) for IP samples at room temperature for 2 h. Then the membranes were incubated briefly with ECL 
Western Blotting substrate (Thermo Fisher Scientific, catalogue number: 32106) after three times wash with 
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TBST. The membranes were exposed to HyBlot Autoradiography Film (Denville Scientific, catalogue number: 
E3018). Antibody information is listed in Supplementary Table 6. 
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